



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 295/22	A1	(11) International Publication Number: WO 98/13358 (43) International Publication Date: 2 April 1998 (02.04.98)
(21) International Application Number: PCT/US97/17267 (22) International Filing Date: 26 September 1997 (26.09.97) (30) Priority Data: 60/026,816 27 September 1996 (27.09.96) US 60/045,917 5 May 1997 (05.05.97) US 60/051,696 3 July 1997 (03.07.97) US (71) Applicant (for all designated States except US): THE UNITED STATES OF AMERICA represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institute of Health [US/US]; Office of Technology Transfer, Suite 325, 6011 Executive Boulevard, Rockville, MD 20852 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): SAAVEDRA, Joseph, E. [US/US]; 7189 Browns Lane, Thurmount, MD 21788 (US). KEEFER, Larry, K. [US/US]; 7016 River Road, Bethesda, MD 20817 (US). SRINIVASAN, Aloka [-/US]; 7 Livingstone Terrace, Frederick, MD 21702 (US). BOGDAN, Christian [DE/DE]; Freidrich-Alexander-Universitat, Erlangen-Numberg, Institut Fur Klinische, Mikrobiologie und Immunologie, Wasserturmstrasse, D-91054 Erlangen (DE). RICE, William, G. [US/US]; 625 Magnolia Avenue, Fred-		erick, MD 21701 (US). Ji, Xinhua [CN/US]; 10218 Crested Iris Drive, Gaithersburg, MD 20879 (US). (74) Agents: GAGALA, Bruce, M. et al.; Leydig, Voit & Mayer, Ltd., Two Prudential Plaza, Suite 4900, 180 North Stetson, Chicago, IL 60601-6780 (US). (81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: O ² -ARYLATED OR O ² -GLYCOSYLATED 1-SUBSTITUTED DIAZEN-1-IUM-1,2-DIOLATES AND O ² -SUBSTITUTED 1-[(2-CARBOXYLATO)PYRROLIDIN-1-YL]DIAZEN-1-IUM-1,2-DIOLATES		
(57) Abstract Diazeniumdiolates, wherein the N ¹ position is substituted by an inorganic or organic moiety and the O ² -oxygen is bound to a substituted or unsubstituted aromatic group, are provided. Also provided are O ² -glycosylated 1-substituted diazen-1-ium-1,2-diolates (O ² -glycosylated diazeniumdiolates) and O ² -substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates (1-[(2-carboxylato)pyrrolidin-1-yl]diazeniumdiolates). The O ² -aryl diazeniumdiolates are stable with respect to the hydrolytic generation of nitric oxide in neutral to acidic solutions and generate nitric oxide in basic or nucleophilic environments or microenvironments. Also provided are compositions, including pharmaceutical compositions, comprising such compounds and methods of using such compounds.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NI	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Licchtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

O²-ARYLATED OR O²-GLYCOSYLATED 1-SUBSTITUTED DIAZEN-1-IUM-1,2-DIOLATES AND O²-SUBSTITUTED 1-[(2-CARBOXYLATO)PYRROLIDIN-1-YL]DIAZEN-1-IUM-1,2-DIOLATES

5 TECHNICAL FIELD OF THE INVENTION

The present invention relates to O²-aryl 1-substituted diazen-1-ium-1,2-diolates (O²-aryl diazeniumdiolates) O²-glycosylated 1-substituted diazeniumdiolates, and O²-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazeniumdiolates, 10 compositions comprising such diazeniumdiolates, methods of using such diazeniumdiolates, and methods of preparing O²-aryl diazeniumdiolates.

15 BACKGROUND OF THE INVENTION

Nitric oxide (NO) has been implicated in a wide variety of bioregulatory processes, and compounds, which contain nitric oxide or are capable of releasing nitric oxide, have been identified as useful in regulating these 20 processes. Many classes of nitric oxide-containing and/or -releasing adducts are known in the art, such as glyceryl trinitrate and nitroprusside (reviewed in U.S. Patent No. 5,405,919 (Keefer et al.), including limitations of their use in biological applications). 25 The limited utility of such compounds has, in part, given rise to the development of another class of nitric oxide-generating compounds, diazeniumdiolates, which are especially useful biologically.


Diazeniumdiolates include compounds containing an 30 N₂O₂⁻ functional group and are structurally and functionally distinct from nitrosamines (see, e.g., Reilly, U.S. Patent No. 3,153,094). The known diazeniumdiolates are disclosed in recently issued patents. U.S. Patent Nos. 5,039,705 (Keefer et al.) and 35 5,208,233 (Keefer et al.) disclose secondary amine-nitric oxide adducts and salts thereof. U.S. Patent Nos. 5,155,137 (Keefer et al.) and 5,250,550 (Keefer et al.) disclose complexes of nitric oxide and polyamines. U.S.

Patent No. 5,389,675 (Christodoulou et al.) discloses mixed ligand metal complexes of nitric oxide-nucleophile adducts and U.S. Patent Nos. 5,525,357 (Keefer et al.) and 5,405,919 (Keefer et al.) disclose polymer-bound
 5 nitric oxide/nucleophile adduct compositions. U.S. Patent Nos. 4,954,526 (Keefer et al.; the '526 patent) and 5,212,204 (Keefer et al.) disclose the use of ionic diazeniumdiolates as cardiovascular agents. In addition, the '526 patent discloses O²-substituted and metal-bound
 10 diazeniumdiolates. Keefer et al., U.S. Patent No. 5,366,997 ('997), discloses diazeniumdiolates having the formula:



in which the O²-oxygen of the N₂O₂⁻ group is bonded to the functional group R³. When the R³ group is cleaved from
 20 the O²-oxygen, NO can be released spontaneously.

Although Keefer et al. ('997) discloses that (i) R¹ and R², together with the nitrogen atom to which they are bonded, can form a pyrrolidinyl, piperazino or other heterocyclic group, (ii) R³ is a C₁₋₁₂ straight-chain or
 25 C₃₋₁₂ branched-chain alkyl, optionally olefinic and/or substituted with hydroxy, halo, acyloxy or alkoxy, a C₁₋₁₂ unsubstituted/substituted acyl, sulfonyl, carboxamido, sulfinyl, sulfenyl, a carbonate derivative or a carbamate derivative, and (iii) the pyrrolidinyl group can have the
 30 structure:



wherein w=4, and R⁴=hydrogen, a C₁₋₈ straight or branched
 35 chain alkyl, a C₃₋₈ cycloalkyl, or a substituted or an

unsubstituted aryl, Keefer et al. ('997) does not disclose that R^3 is an aryl or a substituted aryl or that the pyrrolidino group can be substituted with a substituted or unsubstituted carboxyl group (see, also, Example 1 of U.S. Patent No. 5,632,981) at position 2. Similarly, Keefer et al. ('997) does not disclose O^2 -glycosylation of diazeniumdiolates.

Heretofore it was not known that O^2 -aryl substitutions of the diazeniumdiolates was possible. Further, chemical studies of previously disclosed diazeniumdiolates led to the conclusion that they are generally at least as stable at high pH as they are at low pH, and that, unlike certain other classes of "nitrovasodilator" drugs, their rates of NO release are not affected by the presence of nucleophilic thiols.


Thus, there remains a need for such classes of diazeniumdiolates, which offer advantages over other currently available diazeniumdiolates. In this regard, the O^2 -aryl substituted diazeniumdiolates are advantageous in that they can release NO spontaneously under alkaline conditions or after nucleophilic attack. O^2 -Aryl substituted diazeniumdiolates also can release NO spontaneously after a combination of oxidative or electrophilic activation and nucleophilic attack.

It is, therefore, a principal object of the present invention to provide a nitric oxide/nucleophile adduct in which the O^2 -oxygen of the $N_2O_2^-$ group is derivatized with an aryl or substituted aryl group to protect the diazeniumdiolate against the spontaneous release of NO. It is another object of the invention to provide a novel class of diazeniumdiolates, which resists releasing nitric oxide in neutral or acidic solutions, but releases NO on nucleophilic attack or on increasing the pH. It is still another object of the present invention to provide O^2 -glycosylated 1-substituted diazen-1-ium-1,2-diolates and O^2 -substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates. It is a further object of

the present invention to provide compositions comprising such compounds, including compositions comprising a nitric oxide/nucleophile adduct comprising a novel targeting moiety. It is a related object to provide O²-aryl substituted diazeniumdiolates, which are amenable to biological tissue-targeting strategies, which offer greater flexibility and specificity for targeting NO release. It is a still further object of the present invention to provide methods of using such compounds. These and other objects of the present invention, as well as additional inventive features, will be apparent from the description of the invention provided herein.

BRIEF SUMMARY OF THE INVENTION

The present invention provides an O²-aryl substituted diazeniumdiolate (i.e., O²-aryl diazeniumdiolate) illustrated by the formula:



wherein X is an inorganic or organic moiety and Q is an aryl moiety. In this novel class of compounds an atom of the aryl ring moiety Q is bonded to the O²-oxygen of the N₂O₂⁻ functional group. The diazeniumdiolates of Formula (I) are stable with respect to the hydrolytic generation of nitric oxide in neutral to acidic solutions. Surprisingly, these novel compounds, or the resultant product of these compounds after oxidative or electrophilic activation, have proven capable of generating nitric oxide in basic or nucleophilic environments, in which the aryl moiety is separated from the remainder of the diazeniumdiolate.


The present invention also provides O²-glycosylated 1-substituted diazen-1-ium-1,2-diulates and O²-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diulates, both of which can be represented by the formula:




5 in which X and R are organic and/or inorganic moieties as defined herein, although for O²-glycosylated diazeniumdiolates, R must be a saccharide.

Further with respect to the O²-glycosylated 1-substituted diazen-1-ium-1,2-diulates, the moiety X can
 10 be any organic or inorganic group. Preferably, X contains atoms other than carbon and hydrogen, and is linked to the nitrogen of the diazeniumdiolate through an atom other than carbon. Most preferably, X is an amino group, and is linked to the nitrogen of the
 15 diazeniumdiolate through a nitrogen atom.

With respect to the O²-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diulates, X of Formula Ia can be





20 such that the [1-(2-carboxylato)pyrrolidin-1-yl]diazeniumdiolates can be structurally represented by the formula:




25 wherein R²² is hydrogen, hydroxyl, OM, wherein M is a cation, halo, or X¹R²³R²⁴, wherein X¹ is oxygen, nitrogen or sulfur and R²³ and R²⁴ are independently a substituted or unsubstituted C₁₋₂₄ alkyl, a substituted or unsubstituted C₃₋₂₄ cycloalkyl, a substituted or
 30 unsubstituted C₂₋₂₄ olefinic, a substituted or


unsubstituted aryl (such as acridine, anthracene, benzene, benzofuran, benzothiophene, benzoxazole, benzopyrazole, benzothiazole, carbazole, chlorophyll, cinnoline, furan, imidazole, indole, isobenzofuran, isoindole, isoxazole, isothiazole, isoquinoline, naphthalene, oxazole, phenanthrene, phenanthridine, phenothiazine, phenoxazine, phthalimide, phthalazine, phthalocyanine, porphin, pteridine, purine, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrocoline, pyrrole, quinolizinium ion, quinoline, quinoxaline, quinazoline, sydnone, tetrazole, thiazole, thiophene, thyroxine, triazine, and triazole), or a heterocyclic group, such as glycosyl, and the like, and when X^1 is O or S, there is no R^{24} group. Alternatively, when X^1 is nitrogen, R^{23} and R^{24} , together with X^1 , form a heterocyclic ring, such as a heterocyclic ring selected from the group consisting of:



20



, and



in which A is N, O, or S, w is 1-12, y is 1 or 2, z is

1-5, R^8 , R^9 , R^{25} , and R^{26} are hydrogen, a C_{1-8} straight chain alkyl, a C_{3-8} branched chain alkyl, a C_{3-8} cycloalkyl, or an aryl. The aforementioned R^{23} and R^{24} groups can be unsubstituted or substituted as appropriate. For example, the R^{23} and R^{24} groups can be substituted as appropriate with acyloxy, acylthio, hydroxyl, amino, carboxyl, mercapto, halo, amido, sulfonyl, sulfoxy, sulfenyl, phosphono, phosphato, and the like.

Further with respect to the O^2 -substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazene-1-ium-1,2-diols, the moiety R of Formula Ia can be any organic or inorganic moiety, which is covalently bound to the terminal oxygen of the diazeniumdiolate as shown but which is other than hydrogen and is a substituted or unsubstituted C_{1-12} straight chain or C_{3-12} branched chain alkyl, a substituted or unsubstituted C_{2-12} straight chain or C_{3-12} branched chain olefinic, a substituted or unsubstituted C_{1-12} acyl, sulfonyl, carboxamido, a glycosyl group, an aryl group, or a group of the formula $-(CH_2)_n-ON=N(O)NR^{28}R^{29}$, wherein n is an integer of 2-8, and R^{28} and R^{29} are independently a C_{1-12} straight chain alkyl, a C_{3-12} branched chain alkyl, a C_{2-12} straight chain or C_{3-12} branched chain olefinic, or R^{28} and R^{29} , together with the nitrogen atom to which they are bonded, form a heterocyclic group, preferably a pyrrolidino, piperidino, piperazino or morpholino group. The aforementioned R groups can be unsubstituted or substituted. Preferred substitutions include those made with hydroxy, halo, acyloxy, alkoxy, acylthio, or benzyl.

In another aspect, the present invention comprises a composition, including a pharmaceutical composition, comprising a present inventive diazeniumdiolate. The pharmaceutical composition preferably additionally comprises a pharmaceutically acceptable carrier.

In yet another aspect, the present invention provides methods of using a compound in accordance with the present invention.

In still another aspect, the present invention
5 provides a method of making O²-aryl diazeniumdiolates.

BRIEF DESCRIPTION OF THE DRAWINGS


Figure 1 is a graph of Trp37 fluorescence (RFU) versus time (min), which depicts zinc ejection from HIV-1
10 nucleocapsid p7 protein by O²-aryl diazeniumdiolates. In the graph, ○ represents the negative control, i.e., no drug, □ represents the positive control, i.e., 624151 (See Rice et al., Antimicrob. Agents Chemother. 41: 419426 (1997)), ■ represents the compound of Example 1
15 (LK1), ♦ represents the compound of Example 8 (LK2), ▲ represents the compound of Example 5 (LK3), • represents the compound of Example 10 (LK4), and × represents the compound of Example 11 (LK5).

Figure 2 is a graph of relative NO release rate
20 versus time (min), which depicts the catalysis of NO release from DNP-PYRRO/NO by glutathione S-transferase (GST).

DETAILED DESCRIPTION OF THE INVENTION

25 O²-arylated diazeniumdiolates

The present invention provides an O²-aryl 1-substituted diazeniumdiolate (i.e., O²-aryl 1-substituted diazen-1-ium-1,2-diolate) having the formula:



wherein X is an organic or inorganic moiety and Q is an aryl group.

In accordance with the invention, the O²-oxygen of the N₂O₂⁺ group is bonded directly to an atom of the ring
35 of the aryl group. Stated another way, there are no

spacer atoms (e.g., methylene) that separate the O²-oxygen from the aryl ring. If the aryl group comprises a bicyclic or polycyclic moiety and all rings of the aryl group are not aromatic, then the linkage between the O²-oxygen and the aryl group is through an atom that is part of an aromatic ring. Further, the O²-oxygen can be linked to any aromatic ring atom of the aryl group that is capable of bonding to the O²-oxygen of the N₂O₂⁻ group. Atoms of the aromatic ring that are capable of bonding with the O²-oxygen of the N₂O₂⁻ group are typically carbon and nitrogen, although there can be other linkages as well.

While not wishing to be bound to any particular theory, it is presently believed that the bonding of the O²-oxygen with the atom of the aryl ring is accomplished by bonding to an activated atom of the ring. Activation can be accomplished through any suitable mechanism. In this regard, a preferred mechanism of activating an aryl ring is by reacting the diazeniumdiolate through an atom of the aryl ring possessing a partial positive charge or, more specifically, by displacing an amino substituent of the ring structure.

In the first preferred reaction mechanism, the aryl ring is substituted by a suitable electron-withdrawing group(s), which can be part of the ring, as in Example 12, and a "leaving group" prior to reaction with the diazeniumdiolate. It will be appreciated by those skilled in the art that the electron-withdrawing group and the leaving group can, in some instances, be the same moiety. The leaving group is displaced by the diazeniumdiolate to form the O²-aryl diazeniumdiolate of the present invention. Suitable leaving groups include, but are not limited to, F, Cl, Br, I, NO₂, OSO₂R, and OSO₃R, wherein R is an organic moiety, a metal center, or the like, the composition of which is well understood by those skilled in the art. By way of illustration and not in limitation, suitable R groups include H, alkyl,

alkenyl, or aryl. This reaction mechanism is based on the well known S_NAr mechanism; for example, see Nucleophilic Aromatic Displacement: The Influence of the Nitro Group, Francois Terrier, VCH Publishing, Inc., New York, New York, pages 1-11 (1991). Preferably, these S_NAr reactions are carried out in electron-deficient aromatic rings comprising at least one electron-withdrawing group.

In the second preferred reaction mechanism, an aryl reactant is substituted by a suitable amino group, which allows direct derivatization (e.g., after diazotization of the amino group) of the ring atom of the aryl group that is bound to the displaced amino group. There is no requirement for the atom of the aryl ring linked to the O^2 -oxygen to be activated after it has been incorporated into the present inventive compound. However, if this atom is activated after being incorporated into the present inventive compound, then the diazeniumdiolate moiety to which it is bound may be displaced through further nucleophilic displacement (e.g., in a suitably strong base). Alternatively, an oxidative or electrophilic activation event can alter the present inventive compound so that the aryl ring atom linked to the O^2 -oxygen becomes activated, thereby rendering the compound subject to further nucleophilic displacement, as observed above.

Advantageously, the compounds of the present invention have new and useful properties, which are not possessed by other nitric oxide/nucleophile adducts previously known in the art. In general, the compounds of the present invention are stable at neutral or acidic pH (i.e., at neutral or acidic pH, the compounds indicated by Formula I do not generate NO). Another advantageous property of the compounds of the present invention is that the O^2 -aryl linkage is often susceptible to cleavage by nucleophiles, including hydroxide ions. When the typical O^2 -aryl diazeniumdiolate or the

oxidatively or electrophilically activated O²-aryl diazeniumdiolate of the present invention is placed into a basic or nucleophilic environment, the aryl linkage to the O²-oxygen can be broken. The resulting

5 diazeniumdiolate ion spontaneously degrades via a predictable, first order mechanism, giving rise to NO. The resulting aryl group is substituted with a nucleophile provided by the environment. If the nucleophile provided by the environment is part of an

10 enzyme, that enzyme can be inactivated. The susceptibility to nucleophilic attack of the O²-aryl diazeniumdiolates also makes them particularly amenable to designing prodrugs for targeting nitric oxide to nucleophilic tissue components, body sites and

15 microenvironments in the body.

The compounds of the present invention are also useful to identify and quantify individual thiols (organic -SH containing compounds) when the thiols are present in mixtures. For example, a sample suspected to

20 consist of C₄-C₈ straight-chain thiols can be analyzed by dissolving the product of Example 1 in tetrahydrofuran or another inert solvent, then mixing a molar excess of the resulting solution with the sample to be assayed. After the ensuing reaction is complete, an aliquot is subjected

25 to HPLC analysis using an ultraviolet detection system. Peaks found in the resulting chromatogram can be identified by comparing their retention times to those of independently derivatized authentic standards of the individual C₄-C₈ straight-chain thiols, and quantified by

30 transforming peak areas to concentrations via the individual standard curves.

With respect to the O²-aryl diazeniumdiolates, "aryl group" as used herein refers to any aromatic group, regardless of whether it is part of a (homo)cyclic,

35 heterocyclic, or polycyclic structure. The standard understanding of "aromatic" is used herein (See, e.g., L.G. Wade, Jr., Organic Chemistry, 2d Edition, Prentice

Hall, Englewood Cliffs, New Jersey, 682-683 (1991)). The aryl group, as used herein, can also have a wide variety of substituent groups. Any suitable aryl substituent can be used providing that the substituent does not destroy the aromaticity of the aryl ring.


Turning to the aryl group Q of Formula I, Q is intended to include all aryl groups that are (or can be made) amenable to reaction with the O²-oxygen atom of a diazeniumdiolate. The moiety Q thus includes homocyclic, heterocyclic, and polycyclic aromatic structures as well as derivatives thereof. Illustrative of the aryl groups Q are acridine, anthracene, benzene, benzofuran, benzothiophene, benzoxazole, benzopyrazole, benzothiazole, carbazole, chlorophyll, cinnoline, furan, imidazole, indole, isobenzofuran, isoindole, isoxazole, isothiazole, isoquinoline, naphthalene, oxazole, phenanthrene, phenanthridine, phenothiazine, phenoxazine, phthalimide, phthalazine, phthalocyanine, porphin, pteridine, purine, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrocoline, pyrrole, quinolizinium ion, quinoline, quinoxaline, quinazoline, sydnone, tetrazole, thiazole, thiophene, thyroxine, triazine, and triazole.

In keeping with the invention, each of these aromatic compounds Q can be variably derivatized with the numerous substituents well known in the art that are capable of being substituted into an aromatic ring so long as the aromaticity of the ring is maintained. For example, the substituents of the aryl moiety, Q, can include X[N(O)NO]⁻, wherein X is as defined hereinafter and is the same as X of Formula I, halo, hydroxy, alkylthio, arylthio, alkoxy, aryloxy, amino, mono- or di-substituted amino, ammonio or substituted ammonio, nitroso, cyano, sulfonato, mercapto, nitro, oxo, C₁-C₂₄ aliphatic, C₃-C₁₂ olefinic, C₃-C₂₄ cycloalkyl, C₃-C₂₄ heterocycloalkyl, benzyl, phenyl, substituted benzyl, substituted phenyl, benzylcarbonyl, phenylcarbonyl,

saccharides, substituted benzylcarbonyl, substituted phenylcarbonyl and phosphorus derivatives. Illustrative phosphorus derivatives include phosphate and phosphono moieties. Illustrative phosphate moieties include

5 (OH)₂P(O)O- and substituted (OH)₂P(O)O-moieties, wherein one or more oxygen atoms can be independently replaced by S or NR', wherein R' is understood to be a C₁-C₁₀ containing aliphatic, cycloalkyl, or aryl group. Illustrative C₁-C₂₄ aliphatic substituents comprise C₁-C₂₄

10 acyl, and



wherein R is hydrogen, substituted or unsubstituted C₁-C₂₃

15 aliphatic, substituted or unsubstituted C₃-C₂₃ cycloalkyl, substituted or unsubstituted C₃-C₁₂ olefinic, benzyl, phenyl, substituted benzyl or substituted phenyl, and said substituted benzyl or substituted phenyl is substituted with one to five substituents selected from

20 the group consisting of nitro, halo, hydroxy, C₁-C₂₄ alkyl, C₁-C₂₄ alkoxy, amino, mono-C₁-C₂₄ alkylamino, di-C₁-C₂₄ alkylamino, cyano, phenyl and phenoxy. Preferred saccharides include ribose, glucose, deoxyribose, dextran, starch, glycogen, lactose, fucose,

25 galactose, fructose, glucosamine, galactosamine, heparin, mannose, maltose, sucrose, sialic acid, and cellulose. Other preferred saccharides are phosphorylated, 3,5-cyclophosphorylated, and polyphosphorylated hexoses and pentoses.

30 Examples of substituted aryl compounds of the present invention that can be linked to the diazeniumdiolate group comprise dinitrophenol (a benzene), hypoxanthine (a purine), uridine (a pyrimidine), vitamin K₅ (a naphthalene) and ribosyl uridine


35 (a nucleoside).

In another particular embodiment of the present invention, the aryl moiety is identical to or structurally analogous to molecules, or substituents thereof, normally found in living organisms. These
5 biologically relevant groups can be selected from nucleotides, nucleosides, and nucleic acids, peptides, including peptide hormones, non-peptide hormones, vitamins and other enzyme cofactors such as porphyrins, and others. Examples of biologically relevant aryl
10 groups are thyroxine, NAD (or NADH), chlorophyll, hypoxanthine, uridine, and vitamin K₅.


The following reaction schematics illustrate methods of preparing the O²-aryl diazeniumdiolates of the present invention. In these illustrative reactions, in general,
15 a solution of a diazeniumdiolate (X-[N₂O₂⁻]) in 5% aqueous sodium bicarbonate (which is weakly basic) is cooled to 0 °C, preferably under a blanket of inert gas such as nitrogen. A solution containing one equivalent of the activated aromatic reagent in a solvent, such as t-butyl
20 alcohol, dimethyl sulfoxide, or N,N-dimethylformamide, is then added slowly. While not being bound to any particular theory, it is believed that polar non-protic solvents are preferred. The reaction temperature is raised slightly for less reactive aryl moieties, for
25 example, to ambient temperatures or higher. Generally, a precipitate forms upon addition. The mixture is then allowed to warm to room temperature gradually and stirred overnight. The product may be extracted with a suitable extraction agent, such as dichloromethane, and washed
30 subsequently with cold dilute hydrochloric acid and then with sodium bicarbonate solution. The organic layer is dried over a suitable drying agent, such as sodium sulfate, filtered, preferably through a layer of anhydrous magnesium sulfate, and evaporated under vacuum
35 to give the crude product. Usually, the product is solid. Recrystallization from ethanol or other suitable solvents is a preferred method of purifying the product.

It will be appreciated by one skilled in the art that these conditions can be modified to suit the particular application of the artisan. Accordingly, alternative methods of preparation are also embraced.

- 5 Chlorinated quinoline and isoquinoline can be reacted with a diazeniumdiolate such that the Cl substituent is replaced by the O²-oxygen of a diazeniumdiolate, as shown below:




Additionally, quinazoline can be incorporated as shown:




The phthalazines also are incorporated in accordance with the present invention, as indicated:

5




Acridine can be incorporated as indicated:




10



Cinnoline can also be incorporated as indicated:



15 Quinoxaline can also be incorporated as indicated:





Oxygen- and sulfur-containing heteroaromatics can also be used as the aromatic reagent for O²-oxygen substitution of the diazeniumdiolate in accordance with the present invention. For example, oxazole and benzoxazole can be derivatized at the 2-position as indicated:




Similarly, thiazole and benzothiazole can also be derivatized at the 2-position.

15




A derivatized Vitamin K₇ can also be prepared, as indicated:




The O^2 -diazeniumdiolated atom of the aryl ring in the
 5 right-most (directly above) structure is not activated.
 Therefore, the right-most structure is resistant to
 nucleophilic attack, which would re-generate $X-N_2O_2^-$,
 which, in turn, would spontaneously degrade to produce
 NO. Therefore, the right-most structure must undergo
 10 oxidative preactivation prior to nucleophilic attack in
 order to generate NO. This oxidative preactivation
 requirement would also be of advantage in targeting a
 cell or organ type that is uniquely able to perform the
 required oxidation, thereby limiting NO exposure to the
 15 desired tissue while avoiding exposure at other NO-
 sensitive portions of the anatomy.

Illustrative of the class of compounds requiring
 electrophilic preactivation is the compound indicated
 below:

20




Triazines can likewise be the aromatic reagent that forms the O²-aryl substituted diazeniumdiolates of the present invention as shown below. The synthesis of such compounds should enhance the potency of existing triazine-derived herbicides.



Nucleic acids and the nitrogenous bases they comprise (including ribosylated bases) can also be used as the aromatic reagent to form the O²-aryl substituted diazeniumdiolates of the present invention. This is illustrated in Example 13.


Another interesting O²-arylated diazeniumdiolate is the one shown as the product in the reaction below; it can co-generate NO and allopurinol on hydrolysis.




Advantageously, allopurinol is already known to be pharmaceutically useful. Thus, by converting known pharmaceutically useful compounds containing a suitable aryl group to the O²-aryl diazeniumdiolates of the present

invention, the present invention allows existing drugs to be enhanced by the release of NO.

Similarly, a derivative of a biopterin diazeniumdiolate can be prepared from a substituted pteridine, as indicated below.




An example of a suitable aryl substitution that utilizes linkage through a heteroatom is shown in the following scheme which can be effected by reaction with BuONO or other suitable nitrosating agents.



15

A structural analog of Bendazac, a well-known anti-inflammatory agent, can be prepared as indicated:




20

Bendazac

In accordance with the invention, any of the compounds in the class of compounds defined as diazeniumdiolates can be subjected to O²-aryl substitution. Thus, for the compounds having Formula I, X can be any organic or inorganic moiety. Preferably, X contains atoms other than carbon and hydrogen, and is linked to the nitrogen of the N₂O₂⁻ group through an atom other than carbon. Most preferably, X is an amine, and is linked to the nitrogen of the N₂O₂⁻ group through a nitrogen atom. Suitable moieties of X also include, but are not limited to, C₁-C₂₄ aliphatic, aryl, and nonaromatic cyclic. By "aliphatic" is meant acyclic moieties containing carbon and hydrogen and optionally containing nitrogen, oxygen, sulfur, phosphorus, and halogens. By "aryl" is meant, as hereinabove, a moiety containing at least one aromatic ring. Preferably, the aryl moiety is a C₃-C₃₀-containing moiety. By nonaromatic cyclic is meant a moiety containing at least one ring structure and no aromatic rings. Preferably, the non-aromatic cyclic moiety is a C₃-C₃₀-containing moiety.

The moiety X of Formula I can be unsubstituted or substituted with suitable additional moieties, such as, for example, -[N(NO)O⁻], halo, hydroxy, alkylthio, alkoxy, aryloxy, amino, mono- or di- substituted amino, cyano, sulfonato, mercapto, nitro, substituted or unsubstituted C₁-C₁₂ aliphatic, substituted or unsubstituted C₃-C₈ cycloalkyl, substituted or unsubstituted C₃-C₈ heterocycloalkyl, substituted or unsubstituted C₃-C₁₂ olefinic, benzyl, phenyl, substituted benzyl, substituted phenyl, benzylcarbonyl, phenylcarbonyl, saccharides, substituted benzylcarbonyl, substituted phenylcarbonyl and phosphorus derivatives. Illustrative phosphorus derivatives include phosphato and phosphono moieties. Illustrative phosphato moieties include (OH)₂P(O)O⁻ and substituted (OH)₂P(O)O⁻ moieties, wherein one or more oxygen atoms can be independently replaced by S or NR',

wherein R' is understood to be a C₁-C₈-containing aliphatic, cycloalkyl, or aryl group. Preferred C₁-C₁₂ aliphatic substituents comprise C₁-C₁₂ acyl, and




(III),

5 wherein R is C₁-C₁₀ substituted or unsubstituted aliphatic, C₃-C₁₁ olefinic, C₃-C₈ substituted or unsubstituted cycloalkyl, benzyl, phenyl, substituted benzyl or substituted phenyl, and said substituted benzyl or substituted phenyl is substituted with one or two
 10 substituents selected from the group consisting of halogen, hydroxy, C₁-C₄ alkyl, C₁-C₄ alkoxy, amino, mono-C₁-C₄ alkylamino, di-C₁-C₄ alkylamino, phenyl and phenoxy. Preferred saccharides and polysaccharides include ribose, glucose, deoxyribose, dextran, starch, glycogen, lactose,
 15 galactose, fructose, glucosamine, galactosamine, heparin, mannose, maltose, sucrose, sialic acid, and cellulose. Other preferred saccharides are phosphorylated, 3,5-cyclophosphorylated, and polyphosphorylated pentoses and hexoses.

20 In one embodiment of the invention, X is an inorganic moiety as described in U.S. Patent No. 5,212,204. Preferred embodiments of Formula I, in which X is inorganic, are ⁻O₃S- (sulfite) and -O⁻ (oxide).

In another embodiment of the present invention, X is
 25 a polyamine as defined in U.S. Patent No. 5,155,137. Thus, the polyamine substituted O²-aryl diazeniumdiolates have the formula




30 wherein Q is the same as the Q in Formula I and is defined as above, b and d can be the same or different and are zero or one, R¹, R², R³, R⁴, and R⁵ are the same or

different and comprise hydrogen, substituted or unsubstituted C₃-C₈ cycloalkyl, substituted or unsubstituted C₁-C₁₂ straight or branched chain alkyl, substituted or unsubstituted benzyl, substituted or unsubstituted benzoyl, substituted or unsubstituted C₃-C₁₂ olefinic, phthaloyl, acetyl, trifluoroacetyl, p-toluy, t-butoxycarbonyl, or 2,2,2-tri-halo-t-butoxycarbonyl. The values of i, j, and k in Formula II can be the same or different and are integers from 2 to 12.


10 In a preferred embodiment of the present invention the O²-aryl diazeniumdiolates are derived from the compounds disclosed in U.S. Patent Nos. 5,039,705 (Keefer et al.) and 4,954,526 (Keefer et al.) and, thus, have the formula

15



wherein R⁶ and R⁷ can be the same or different and are chosen from H, C₁-C₁₂ straight chain alkyl, C₁-C₁₂ alkoxy or acyloxy substituted straight chain alkyl, C₂-C₁₂ hydroxy or halo substituted straight chain alkyl, C₃-C₁₂ branched chain alkyl, C₃-C₁₂ hydroxy, halo, alkoxy, or acyloxy substituted branched chain alkyl, C₂-C₁₂ straight chain olefinic and C₃-C₁₂ branched chain olefinic, which are unsubstituted or which are substituted with hydroxy, alkoxy, acyloxy, halo or benzyl, provided that both R⁶ and R⁷ are not H; or R⁶ and R⁷, together with the nitrogen atom to which they are bonded, form a heterocyclic ring selected from the group consisting of:


30




wherein A is N, O, or S, w is 1 to 12, y is 1 or 2, z is 1 to 5, R⁸ is hydrogen, C₁-C₈ straight chain alkyl, C₃-C₈ branched chain alkyl, C₃-C₈ cycloalkyl, unsubstituted or substituted aryl, such as phenyl, tolyl or the like, and R⁹ is hydrogen, C₁-C₆ straight chain alkyl or C₃-C₆ branched chain alkyl. Exemplary aza crown groups are 1-aza-12-crown-4, 1-aza-15-crown-5, and 1-aza-18-crown-6.

Where A is nitrogen, the nitrogen atom, itself, can be substituted, as described, for example, in U.S. Application Serial No. 08/475,732, which is incorporated by reference herein.

Further examples include the O²-aryl substituted diazeniumdiolates derived from the compounds disclosed in U.S. Patent No. 5,250,550, previously incorporated in its entirety by reference, and, thus, have the formula




wherein D is



and wherein R¹⁰ and R¹¹ are the same or different. The substituents R¹⁰ and R¹¹ can be any suitable group, examples of which include hydrogen, C₃-C₈ cycloalkyl, C₁-C₁₂ straight or branched chain alkyl, benzyl, benzoyl, phthaloyl, acetyl, trifluoroacetyl, p-toluyyl, t-butoxycarbonyl, and 2,2,2-trihalo-t-butoxycarbonyl. In Formula IV, f is an integer from 0 to 12.

Preferred O²-aryl substituted diazeniumdiolates also include those of Example 14.

An alternative method of preparing O²-arylated diazeniumdiolates is possible through adaptation of the following literature reaction (Stevens, J.Org. Chem. 29: 311-315 (1964)).



By substituting aryloxy anion ArO⁻ for the methoxide of Stevens's reaction, it is possible to obtain O²-aryl diazeniumdiolates of varied structure. Similarly, it is possible to obtain derivatives corresponding to ArS⁻ species.


15 *O²-glycosylated diazeniumdiolates and 1-[(2-carboxylato)pyrrolidin-1-yl] diazeniumdiolates*

The present invention also provides two other new classes of diazeniumdiolates, one class of which contains a hydrolytically labile group (R), which, upon cleavage to the free diazeniumdiolate (NO donor) X-NO=NO⁻, releases an innocuous and possibly beneficial saccharide and allows advantage to be taken of saccharide-based receptor-mediated phenomena. The other class of diazeniumdiolates provides, among others, prodrugs of the salt disodium 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolate (PROLI/NO), which is an ultrafast NO donor of proven effectiveness as an antithrombotic agent and a vasodilator but is inherently extremely difficult to derivatize, due to its instability (Saavedra et al., J. Med. Chem. 31:4361-4365 (1996); and U.S. Patent No. 5,632,981 (Saavedra et al.)). The newly discovered ability to generate prodrugs of the ultrafast NO donor PROLI/NO allows the PROLI/NO prodrugs to move freely through the circulatory system until they reach the desired organ or cell type for metabolic removal of the

stabilizing O²-protecting group, thereby providing a rapid release of NO at the specific or preferred site and obviating the need for administration by infusion at a controlled rate in the vicinity of the target tissue.

- 5 Additionally, the corresponding nitrosamine, N-nitrosoproline, if formed in the biological medium, does not pose a carcinogenic threat, unlike other nitrosamines.

Accordingly, the present invention provides O²-glycosylated 1-substituted diazen-1-ium-1,2-diulates (O²-glycosylated diazeniumdiulates) and O²-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diulates (1-[(2-carboxylato)pyrrolidin-1-yl]diazeniumdiulates), both of which can be represented by the formula:




In Formula Ia, X and R are organic and/or inorganic
20 moieties as defined herein.

O²-GLYCOSYLATED DIAZENIUMDIOLATES


With respect to the O²-glycosylated diazeniumdiulates, any of the compounds in the class of
25 compounds defined as diazeniumdiulates (see e.g., U.S. Patent Nos. 5,039,705, 5,208,233, 5,155,137, 5,250,550, 5,389,675, 5,525,357, 5,405,919 and related patents and patent applications) can be subjected to O²-glycosylation, provided that the O² of the diazeniumdiolate is available
30 for glycosylation. The moiety R of Formula Ia can be any saccharide, which is attached to the O² of the diazeniumdiolate by the 2 position of a pyranose or furanose ring. The saccharide can be functionalized. Desirably, the saccharide and its derivatives are
35 hydrolyzable at physiological pH. The saccharide can be a monosaccharide, disaccharide, such as sucrose or maltose, an oligosaccharide or a polysaccharide. Preferred saccharides and polysaccharides include, among

others, ribose, glucose, deoxyribose, fucose, lactose, galactose, fructose, glucosamine, galactosamine, mannose, maltose, sucrose, and the many saccharide and oligosaccharide units that serve as recognition sequences in receptor-mediated cellular interactions. Other preferred saccharides include those that are phosphorylated, 3,5-cyclophosphorylated, and polyphosphorylated pentoses and hexoses.

By way of illustration, the saccharide residue (shown attached to the diazeniumdiolate for illustrative purposes) can be an amino sugar, such as a glucosamine or a substituted glucosamine having the structure:



wherein R^{12} and R^{13} can be the same or different and are a hydrogen, a C_{1-6} alkyl, an acyl, a phosphate, a sulfate, a peptide or a protein. The saccharide residue can be, for example, glucuronic acid or a derivative thereof:




20

wherein R^{14} is $X^1R^{15}R^{16}$, wherein X^1 is N, O or S and, when X^1 is N, R^{15} and R^{16} are independently a hydrogen or a substituted or an unsubstituted C_{1-24} alkyl, C_{3-24} cycloalkyl, C_{2-24} olefinic, aryl (such as acridine, anthracene, benzene, benzofuran, benzothiophene, benzoxazole, benzopyrazole, benzothiazole, carbazole, chlorophyll, cinnoline, furan, imidazole, indole,

25

isobenzofuran, isoindole, isoxazole, isothiazole, isoquinoline, naphthalene, oxazole, phenanthrene, phenanthridine, phenothiazine, phenoxazine, phthalimide, phthalazine, phthalocyanine, porphin, pteridine, purine, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrocoline, pyrrole, quinolizinium ion, quinoline, quinoxaline, quinazoline, sydnone, tetrazole, thiazole, thiophene, thyroxine, triazine, and triazole), or heterocyclic group, such as glycosyl and the like, and when X^1 is O or S, there is no R^{16} group.

Alternatively, when X^1 is nitrogen, R^{15} and R^{16} form a heterocyclic ring selected from the group consisting of:




wherein A is N, O, or S, w is 1-12, y is 1 or 2, z is 1-5, R^8 is hydrogen, a C_{1-8} straight chain alkyl, a C_{3-8} branched chain alkyl, a C_{3-8} cycloalkyl, an aryl (such as phenyl, tolyl or the like), or carboxylato and derivatives thereof as further described herein, and R^9 is hydrogen, a C_{1-6} straight chain alkyl or a C_{3-6} branched chain alkyl. The aforementioned groups can be unsubstituted or substituted as appropriate.

Exemplary aza crown groups (i.e., where A is N) are 1-aza-12-crown-4, 1-aza-15-crown-5, and 1-aza-18-crown-6. Where A is nitrogen, the nitrogen atom, itself, can be substituted, as described, for example, in U.S. patent application serial no. 08/475,732.

Further with respect to the O^2 -glycosylated diazeniumdiolates, the moiety attached to the carbonyl group through X^1 can be anything that does not interfere with the cleavage to the diazeniumdiolate anion.

Further with respect to the O²-glycosylated diazeniumdiolates, the moiety attached to the carbonyl group through X¹ can be anything that does not interfere with the cleavage to the diazeniumdiolate anion.


- 5 Preferably, the moiety X contains atoms other than carbon and hydrogen, and is linked to the nitrogen of the N₂O₂⁻ group through an atom other than carbon. Most preferably, X is an amino group, and is linked to the nitrogen of the N₂O₂⁻ group through a nitrogen atom.
- 10 Suitable moieties of X include, but are not limited to, C₁₋₂₄ aliphatic, aryl and non-aromatic cyclic groups. By "aliphatic" is meant an acyclic moiety containing carbon and hydrogen and optionally containing nitrogen, oxygen, sulfur, phosphorus or a halogen. By "aryl" is meant a
- 15 moiety containing at least one aromatic ring. Preferably, the aryl moiety is a C₆₋₃₀ moiety. By "non-aromatic cyclic" is meant a moiety containing at least one ring structure and no aromatic rings. Preferably, the non-aromatic cyclic moiety is a C₆₋₃₀ moiety. Further,
- 20 X can be unsubstituted or substituted with suitable additional moieties, such as, for example, -[N(NO)O⁻], a halo, a hydroxy, an alkylthio, an alkoxy, an aryloxy, an amino, a mono- or di- substituted amino, a cyano, a sulfonato, a mercapto, a nitro, a substituted or
- 25 unsubstituted C₁₋₁₂ aliphatic, a substituted or unsubstituted C₃₋₈ cycloalkyl, a substituted or unsubstituted C₃-C₁₂ olefinic, a substituted or unsubstituted C₃₋₈ heterocycloalkyl, a benzyl, a phenyl, a substituted benzyl, a substituted phenyl, a
- 30 benzylcarbonyl, a phenylcarbonyl, a saccharide, a substituted benzylcarbonyl, a substituted phenylcarbonyl and a phosphorus derivative. Illustrative phosphorus derivatives include phosphato and phosphono moieties. Illustrative phosphato moieties include (OH)₂P(O)O⁻ and
- 35 substituted (OH)₂P(O)O⁻ moieties, wherein one or more oxygen atoms can be independently replaced by S or NR¹⁷, wherein R¹⁷ is understood to be a C₁₋₃ aliphatic, a



- 5 wherein R¹⁸ is a C₁₋₁₀ unsubstituted or substituted aliphatic, a C₃₋₈ unsubstituted or substituted cycloalkyl, benzyl, phenyl, substituted benzyl or substituted phenyl. When the benzyl or phenyl is substituted, preferably it is substituted with one or two substituents selected from
 10 the group consisting of halogen, hydroxy, a C₁₋₄ alkyl, a C₁₋₄ alkoxy, an amino, a mono-C₁₋₄ alkylamino, a di-C₁₋₄ alkylamino, phenyl and phenoxy.

- In one embodiment of the invention, X in Formula Ia is an inorganic moiety as described in U.S. Patent No.
 15 5,212,204. Preferred embodiments of Formula Ia, in which X is inorganic, are ⁻O₃S- (sulfite) and -O⁻ (oxide).

- In another embodiment of the present invention, X in Formula Ia is a polyamine as defined in U.S. Patent No. 5,250,550. Thus, the polyamine O²-glycosylated
 20 diazeniumdiolates have the formula




(II),

25

- wherein Q is the same as the R in Formula Ia and is defined as above, b and d can be the same or different and
 30 are zero or one, R¹, R², R³, R⁴, and R⁵ are the same or different and are hydrogen, substituted or unsubstituted C₃₋₈ cycloalkyl, substituted or unsubstituted C₁₋₁₂ straight or branched chain alkyl, substituted or unsubstituted benzyl, substituted or unsubstituted benzoyl, substituted
 35 or unsubstituted C₃-C₁₂ olefinic, phthaloyl, acetyl, trifluoroacetyl, p-toluyyl, t-butoxycarbonyl, or 2,2,2-tri-halo-t-butoxycarbonyl. The values of i, j, and k in


Formula II can be the same or different and are integers from 2 to 12.

In a preferred embodiment of the present invention, the diazeniumdiolates are derived from the compounds disclosed in U.S. Patent Nos. 5,039,705 (Keefer et al.) and 4,954,526 (Keefer et al.), and, thus, have the formula



wherein R is the same as the R in Formula Ia and is defined as above, R^{19} and R^{20} are the same or different and are hydrogen, a C_{1-12} straight chain alkyl, a C_{3-12} branched chain alkyl, or a C_{2-12} straight or C_{3-12} branched chain olefinic, provided that both R^{19} and R^{20} are not hydrogen. Any of the aforementioned substituents can be unsubstituted or substituted with an alkoxy, an acyloxy, an acylthio, a hydroxy, a halo or a benzyl group.

Alternatively, R^{19} and R^{20} , together with the nitrogen atom to which they are bonded, form a heterocyclic ring selected from the group consisting of:



25

wherein A is N, O, or S, w is 1-12, y is 1 or 2, z is 1-5, R^8 is hydrogen, a C_{1-8} straight chain alkyl, a C_{3-8} branched chain alkyl, a C_{3-8} cycloalkyl, a substituted or an unsubstituted aryl (such as phenyl, tolyl or the like), or carboxylato and derivatives thereof as further described herein, and R^9 is hydrogen, a C_{1-6} straight chain alkyl or

a C₃₋₆ branched chain alkyl. The aforementioned groups can be unsubstituted or substituted as appropriate.


Exemplary aza crown groups (i.e., where A is N) are 1-aza-12-crown-4, 1-aza-15-crown-5, and 1-aza-18-crown-6.

5 Where A is nitrogen, the nitrogen atom, itself, can be substituted, as described, for example, in U.S. patent application serial no. 08/475,732.

Further examples include the O²-glycosylated diazeniumdiolates derived from the compounds disclosed in
10 U.S. Patent No. 5,250,550, and, thus, have the formula



15 wherein D is



20 and wherein R²¹ is the same as the R in the saccharide of Formula Ia and is defined as above, and R¹⁰ and R¹¹, which can be the same or different, can be any suitable group, examples of which include hydrogen, a C₁₋₈ cycloalkyl, a C₁₋₁₂ straight or branched chain alkyl, benzyl, benzoyl,
25 phthaloyl, acetyl, trifluoroacetyl, p-toluyyl, t-butoxycarbonyl and 2,2,2-trihalo-t-butoxycarbonyl. In Formula IV, f is an integer from 0 to 12.

A preferred O²-glycosylated diazeniumdiolate is one in which, with respect to Formula Ia, X is N(CH₂CH₂NH₂)₂
30 and R is fucose or mannose.

The above compounds can be prepared in accordance with methods known to those of skill in the art. Reagents for glycopyranosylation include acetobromo- α -galactose and acetobromoglucosamine. Reagents for
35 glycofuranosylation include tribenzyl- α -arabinofuranosyl bromide and bromoacetylxylose.

Oligosaccharides are commercially available from, for example, Sigma Chemical Co. (St. Louis, MO) and


Carbomer Specialty Biochemicals and Polymers
(Westborough, MA). In addition, oligosaccharides can be
synthesized in accordance with well-established
procedures, including chemical and enzymatic preparation,
5 such as those described in Preparative Carbohydrate
Chemistry, Stephen Hanessian, ed., Marcel Dekker, New
York, NY (1997) and Polysaccharides in Medicinal
Applications, Severian Dumitriu, ed., Marcel Dekker, New
York, NY (1996).

10 A protected straight- or branched-chain
polysaccharide can be activated toward reaction with the
diazoniumdiolate ion by halogenation of the anomeric
terminus, followed by glycosylation of the
diazoniumdiolate. Activated disaccharides for generation
15 of O²-glycosylated diazoniumdiolates include acetobromo-
α-maltose and acetobromo-α-lactose.


O²-Glycosylated diazoniumdiolates are useful where
molecular signalling and recognition processes, including
cell adhesion, involve carbohydrates. For example,
20 O²-glycosylated diazoniumdiolates are believed to be
useful in the treatment of infection, such as that due to
a parasite (e.g., leishmania), a virus or a bacterium, as
well as inflammation and metastasis. In this regard, an
O²-glycosylated diazoniumdiolate can be prepared so as to
25 be directed to a mannose-fucose receptor as exemplified
in Example 36. It is believed that the sugar residue, in
this instance mannose, protects the diazoniumdiolate.
The mannose binds to the mannose-fucose receptor on a
macrophage, and the O²-mannosylated diazoniumdiolate is
30 imported into the cell, where the sugar residue is
cleaved, and NO is released.

1-[(2-CARBOXYLATO)PYRROLIDIN-1-YL]DIAZENIUMDIOLATES




With respect to the 1-[(2-carboxylato)pyrrolidin-1-
35 yl]diazoniumdiolates, the moiety X of Formula Ia can be




such that the 1-[(2-carboxylato)pyrrolidin-1-yl]diazoniumdiolates can be structurally represented by the formula:



- 5 wherein R^{22} is hydrogen, hydroxyl, OM, wherein M is a cation, halo, or $X^1R^{23}R^{24}$, wherein X^1 is N, O or S and, when X^1 is N, R^{23} and R^{24} are independently a substituted or an unsubstituted C_{1-24} alkyl, C_{3-24} cycloalkyl,
- 10 C_{2-24} olefinic, aryl (such as acridine, anthracene, benzene, benzofuran, benzothiophene, benzoxazole, benzopyrazole, benzothiazole, carbazole, chlorophyll, cinnoline, furan, imidazole, indole, isobenzofuran, isoindole, isoxazole, isothiazole, isoquinoline,
- 15 naphthalene, oxazole, phenanthrene, phenanthridine, phenothiazine, phenoxazine, phthalimide, phthalazine, phthalocyanine, porphin, pteridine, purine, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrocoline, pyrrole, quinolizinium ion, quinoline, quinoxaline,
- 20 quinazoline, sydnone, tetrazole, thiazole, thiophene, thyroxine, triazine, and triazole), or heterocyclic group, such as glycosyl, and the like, and when X^1 is O or S, there is no R^{24} group. Alternatively, when X^1 is nitrogen, R^{23} and R^{24} , together with the nitrogen to which
- 25 they are bonded, form a heterocyclic ring, such as a heterocyclic ring selected from the group consisting of:



, and



5

in which A is N, O or S, w is 1 to 12, y is 1 or 2, z is 1 to 5, R^8 , R^9 , R^{25} and R^{26} are hydrogen, a C_{1-8} straight chain alkyl, a C_{3-8} branched chain alkyl, a C_{3-8} cycloalkyl, or an aryl. The aforementioned groups can be unsubstituted or substituted as appropriate.

10

The R^{26} substituent on the nitrogen (N-4) can be a hydrogen, a C_{1-8} alkyl group, an aryl group, or $C(O)-YR^{27}$, wherein Y is sulfur or oxygen, or nitrogen and R^{27} is CH_2OCH_3 , vinyl, a C_{1-9} straight chain alkyl, a C_{3-6} branched chain alkyl, a C_{3-8} cycloalkyl, polyethylene glycol, polysaccharide, or other polymer, a peptide, or a protein. YR^{27} can be an activating linker, such as a hydroxy succinimidyl group, for linkage to proteins, peptides, phospholipids, polysaccharides, oligosaccharides, purines, pyrimidines, and biocompatible polymers (i.e., polyethylene glycol, polylactides, and polycaprolactone). YR^{27} can be an activating moiety for the carbonyl group, making the carbonyl group an electrophilic site that reacts with nucleophilic functionalities of oligopeptides, polyamines and proteins. YR^{27} can cause the carbonyl group to react with many nucleophiles, and can react with a polymer, such as polyethylene glycol, to form a polymer-bound compound.

25

Further with respect to the 1-[(2-carboxylato)pyrrolidin-1-yl]diazoniumdiolates, the moiety R of Formula Ia can be any covalently bound organic or inorganic moiety, which is other than hydrogen and is a

5 C₁₋₁₂ straight chain or C₃₋₁₂ branched chain alkyl, a C₂₋₁₂ straight chain or C₃₋₁₂ branched chain olefinic, a C₁₋₁₂ acyl, sulfonyl, C₃₋₁₂ cycloalkyl, carboxamido, a glycosyl group as described above, an aryl group as described below, or a group of the formula $-(CH_2)_n-ON=N(O)NR^{28}R^{29}$,

10 wherein n is an integer of 2-8, and R²⁸ and R²⁹ are independently a C₁₋₁₂ straight chain alkyl, a C₃₋₁₂ branched chain alkyl, a C₁₋₁₂ straight chain or C₃₋₁₂ branched chain olefinic, or R²⁸ and R²⁹, together with the nitrogen atom to which they are bonded, form a heterocyclic group,

15 preferably a pyrrolidino, piperidino, piperazino or morpholino group. The aforementioned R groups can be unsubstituted or substituted as appropriate. Preferred substitutions include those made with hydroxy, halo, acyloxy, alkoxy, acylthio, or benzyl.

20 The above compounds can be prepared in accordance with methods known to those of skill in the art. For example, see Sanger, Biochem. J. 39: 507-515 (1945).

O²-Substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazoniumdiolates offer advantages over other

25 diazeniumdiolates in that they are more stable in aqueous solution than the O²-unsubstituted anion and, in many cases, they can be activated for NO release by enzymatic action. Furthermore, if an N-nitroso derivative is formed by net formal cleavage of the N-N double bond of

30 the 1-[(2-carboxylato)pyrrolidin-1-yl]diazonium-1,2-diolate, the N-nitroso compound is noncarcinogenic. Such compounds are believed to be particularly useful in the treatment of fulminant liver failure, malaria, respiratory problems, impotence, and a variety of

35 cardiovascular/hematologic disorders.

Polymer Bound Diazeniumdiolates

Another particularly useful embodiment of the present invention comprises O²-aryl diazeniumdiolates of Formula I or O²-glycosylated diazeniumdiolates of Formula Ia, wherein X is a polymer, or wherein any O²-aryl diazeniumdiolate or O²-glycosylated diazeniumdiolate of the present invention is incorporated into a polymeric matrix. PROLI/NO also can be polymer bound--through R²⁰ as well as R. Both of these embodiments result in the N₂O₂⁻ functional group being "bound to the polymer." By "bound to a polymer," it is meant that the N₂O₂⁻ functional group is associated with, part of, incorporated with or contained within the polymeric matrix physically or chemically.

Physical association or bonding of the N₂O₂⁻ functional group to the polymer may be achieved by coprecipitation of the polymer with a nitric oxide/nucleophile complex as well as by covalent bonding of the N₂O₂⁻ group to the polymer. Chemical bonding of the N₂O₂⁻ group to the polymer may be by, for example, covalent bonding of the nucleophilic moiety of the nitric oxide/nucleophile adduct to the polymer such that the nucleophilic residue to which the N₂O₂⁻ group is attached forms part of the polymer, itself, i.e., is in the polymer backbone or is attached to pendant groups on the polymer backbone. The manner in which the nitric oxide-releasing N₂O₂⁻ functional group is associated with, part of, or incorporated with or contained within, i.e., "bound" to the polymer is inconsequential to the present invention and all means of association, incorporation and bonding are contemplated herein.

Site-specific application of the polymer-bound adduct composition enhances the selectivity of action of the nitric-oxide releasing N₂O₂⁻ functional group. If N₂O₂⁻ functional groups attached to the polymer are necessarily localized, then the effect of their nitric oxide release will be concentrated in the tissues with which they are

in contact. If the polymer is soluble, selectivity of action can still be arranged, for example, by linkage to or derivatization of an antibody specific to the target tissue. Similarly, linkage of N_2O_2^- groups to small
5 peptides that mimic the recognition sequences of ligands for important receptors provides localized nitric oxide release, as would linkage to oligonucleotides capable of site-specific interactions with target sequences in a nucleic acid.

10 The O^2 -diazoniumdiolates of the present invention can be derived from the materials disclosed in U.S. Patent Nos. 5,525,357 (Keefer et al.) and 5,405,919 (Keefer et al.), and in U.S. Patent Application Serial No. 08/419,424 (Smith et al.), each of which is incorporated
15 by reference. Any of a wide variety of polymers can be used in the context of the present invention. It is only necessary that the polymer selected is biologically acceptable. Illustrative of polymers suitable for use in the present invention are polyolefins, such as
20 polystyrene, polypropylene, polyethylene, polytetrafluorethylene, polyvinyl chloride, polyvinylidene difluoride, and polyethers such as polyethylene glycol, polysaccharides such as dextran, polyesters such as poly(lactide/glycolide), polyamides
25 such as nylon, polyurethanes, polyethyleneimines, biopolymers such as peptides, proteins, oligonucleotides, antibodies and nucleic acids, starburst dendrimers, polysaccharides, and the like.

In this regard, a polymer containing a
30 diazoniumdiolate can be reacted with a saccharide, such that the saccharide becomes bound to the N_2O_2^- functional group.

Formation of a diazoniumdiolate from a biopolymer provides a biopolymer-bound diazoniumdiolate composition
35 that can be applied with specificity to a biological site of interest. Site-specific application of the biopolymer-bound diazoniumdiolate enhances the

selectivity of action of the nitric oxide-releasing diazeniumdiolate, which occurs following the cleavage of the O²-aryl or O²-glycosylated bond or the O-R bond in PROLI/NO (see pg. 33). As with the other polymers
5 disclosed above, if the diazeniumdiolate attached to the biopolymer is localized because of the inherent properties of the molecule, then the effect of its nitric oxide release will be concentrated in the tissues with which they are in contact. If the biopolymer is soluble,
10 selectivity of action can still be arranged, for example, by attachment to or derivatization of an antibody specific to the target tissue. Similarly, linkage of diazeniumdiolate groups to small peptides that mimic the recognition sequences of ligands for important receptors
15 provides localized nitric oxide release, as would linkage to oligonucleotides capable of site-specific interactions with target sequences in a nucleic acid. Other proteins, peptides, polypeptides, nucleic acids and polysaccharides can be similarly utilized. U.S. Patent No. 5,405,919
20 (Keefer et al.) and U.S. Patent No. 5,632,981 (Saavedra et al.), hereby incorporated in their entireties by reference, disclose similar compounds and manufactures useful in the preparation of the diazeniumdiolates.

By way of illustration, an O²-arylated piperazine
25 diazeniumdiolate can be covalently attached to a polypeptide containing the IKVAV recognition sequence, which is important in tumor cell chemotaxis. Through retention of both the capacity to regenerate NO as an anti-adhesive agent and the affinity of the IKVAV
30 sequence for tumor cells and/or sites in the vascular and lymphatic systems, where the tumor cells tend to attach, metastasis can be reduced or even prevented. Further, the aryl moiety can be chosen such that it provides additional antitumor cell activity. Substitutions at the
35 N⁴ position of piperazine can be used to link the glycosylated diazeniumdiolate to peptides, polypeptides, proteins, polysaccharides and nucleotides.

It is contemplated that the diazeniumdiolates of the present invention can be used to coat prostheses, stents, and medical implants, such as breast implants, prior to surgical connection to the body as a means of reducing the risk of solid state carcinogenesis associated therewith. Additionally, the prostheses and implants can be manufactured using a diazeniumdiolate as an integral component of the starting materials. Medical devices incorporating a diazeniumdiolate provide an invaluable two-pronged approach to the treatment of many biological disorders, providing useful medical structures that also advantageously provide local release of NO.

Compositions

As is well-known in the art, nitric oxide and compounds comprising N_2O_2^- functional groups can have a wide range of utilities, in part because of the multifaceted role of nitric oxide in bioregulatory processes. Accordingly, the present invention also provides a composition, including a pharmaceutical composition, comprising a present inventive diazeniumdiolate. Preferably, the pharmaceutical composition additionally comprises a pharmaceutically acceptable carrier.

One skilled in the art will appreciate that suitable methods of administering the diazeniumdiolate compositions of the present invention to an animal, such as a mammal, are available, and, although more than one route can be used to administer a particular composition, a particular route can provide a more immediate and more effective reaction than another route. Pharmaceutically acceptable carriers are also well-known to those who are skilled in the art. The choice of carrier will be determined, in part, both by the particular composition and by the particular method used to administer the composition. Accordingly, there is a wide variety of

suitable formulations of the pharmaceutical compositions of the present invention.

Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective
5 amount of the diazeniumdiolate dissolved in diluents, such as water or saline, (b) capsules, sachets or-tablets, each containing a predetermined amount of the active ingredient, as solids or granules, (c) suspensions in an appropriate liquid, and (d) suitable emulsions.
10 Tablet forms can include one or more of lactose, mannitol, corn starch, potato starch, microcrystalline cellulose, acacia, gelatin, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, stearic acid, and other excipients, colorants, diluents,
15 buffering agents, moistening agents, preservatives, flavoring agents, and pharmacologically compatible carriers. Lozenge forms can comprise the active ingredient in a flavor, usually sucrose and acacia or tragacanth, as well as pastilles comprising the active
20 ingredient in an inert base, such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addition to the active ingredient, such carriers as are known in the art.

The diazeniumdiolates of the present invention,
25 alone or in combination with other suitable components, can be made into aerosol formulations to be administered via inhalation. These aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like.

30 Formulations suitable for parenteral administration include aqueous and non-aqueous solutions, isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the
35 intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and

preservatives. The formulations can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, water, for injections, immediately prior to use. Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described.

The dose administered to an animal, particularly a human, in the context of the present invention should be sufficient to effect a therapeutic response in the animal over a reasonable time frame. The dose will be determined by the strength of the particular compositions employed (taking into consideration, at least, the rate of NO evolution, the extent of NO evolution, and the bioactivity of the decomposition products derived from the diazeniumdiolates) and the condition of the animal, as well as the body weight of the animal to be treated. The size of the dose also will be determined by the existence, nature, and extent of any adverse side effects that might accompany the administration of a particular composition. A suitable dosage for internal administration is 0.01 to 100 mg/kg per day. A preferred dosage is 0.01 to 35 mg/kg per day. A more preferred dosage is 0.05 to 5 mg/kg per day. A suitable concentration of O²-aryl diazeniumdiolates in pharmaceutical compositions for topical administration is 0.05 to 15% (by weight). A preferred concentration is from 0.02 to 5%. A more preferred concentration is from 0.1 to 3%.

Methods of Use

In view of the above, the present invention provides methods of using a present inventive diazeniumdiolate. In one embodiment, a method of treating an animal, such as a mammal, with a biological disorder treatable with nitric oxide, is provided. The method comprises

administering to the animal, e.g., the mammal, an amount of an diazeniumdiolate in accordance with the present invention sufficient to treat the biological disorder in the animal. In this embodiment, "biological disorder" can be any biological disorder, including a biological disorder due to a genetic defect or infection with an infectious agent, such as a virus, bacterium or parasite, as long as the disorder is treatable with nitric oxide.

In another embodiment of a method of use, a method is provided for treating an animal, such as a mammal, for infection with, for example, a virus, a bacterium, or a parasite (e.g., leishmania). The method comprises administering to the animal, e.g., the mammal, an amount of a diazeniumdiolate sufficient to treat the infection in the animal.

In one aspect of this embodiment of the invention, a method is provided for treating an animal, such as a mammal, for infection with, for example, a virus, such as a retrovirus, in particular HIV, more particularly HIV-1, a bacterium, such as a Gram-positive bacterium, or a parasite, such as *Giardia*, any one of which comprises a zinc finger protein that can be inactivated by an O²-aryl diazeniumdiolate. By "zinc finger protein" is meant a protein comprising a short amino acid domain containing cysteines alone or cysteine and histidine ligands, both of which coordinate with zinc and interact with nucleic acids (South and Summers, "Zinc Fingers," Chapter 7, In: *Adv. Inorg. Biochem. Ser. 8*, pp. 199-248 (1990), which is hereby incorporated by reference in its entirety, including the content of all references cited therein). By "inactivated" is meant partial or complete loss of activity of the zinc finger protein to be inactivated. Such inactivation should not result in inactivation of biologically important zinc finger proteins in the animal, itself, to such an extent as to compromise unduly the health and well-being of the animal. The method comprises administering to the animal, e.g., the mammal,

an amount of an O²-aryl diazeniumdiolate sufficient to inactivate the zinc finger protein in said infectious agent so as to treat the infection in the animal.

The above-described method also can be adapted as a means of treating a plant, plant cell or tissue culture thereof for infection with an infectious agent, such as a virus, e.g., tobacco streak virus (TSV) or alfalfa mosaic virus (AIMV) (South and Summers (1990), *supra*; and Sehnke et al., Virology 168: 48 (1989)).

The methods described herein are useful against zinc fingers comprising the motif C-X₂-C-X₄-H-X₄-C (see, e.g., Wain-Hobson et al., Cell 40(1): 9-17 (1985)), in which "C" represents cysteine, "H" represents histidine, "X" represents any amino acid, and the numbers "2" and "4" represent the number of "X" amino acids. Such a motif is characteristic of retroviruses, in particular the gag protein of retroviruses. Accordingly, the methods herein are useful against retroviruses, such as HIV, and, in particular, HIV-1 (Rice et al., Nature Medicine 3(3): 341-345 (1997); and Rice et al., Reviews in Medical Virology 6: 187-199 (1986)), which comprises nucleocapsid p7 proteins (NCp7 proteins) that include two zinc binding domains. Actual and/or potential zinc fingers also have been identified in, among others, the gene products of the E1A genomic region of adenoviruses, the large T antigens from simian virus 40 (SV40) and polyoma viruses, the UvrA protein in *E. coli* (Culp et al., PNAS USA 85: 6450 (1988)), murine leukemia virus (MuLV-F; Green et al., PNAS USA 86: 4047 (1989)), and bacteriophage proteins (Berg, Science 232: 484 (1986)), such as gene 32 protein (G32P) from bacteriophage T4 (Giedroc et al., Biochemistry 28: 2410 (1989)). Such proteins can be isolated in accordance with methods known in the art (see references cited in South and Summers (1990), *supra*), and the O²-aryl diazeniumdiolates, which can inactivate such zinc finger proteins, can be identified in accordance,

for example, with the zinc finger assay described herein and in Rice et al., J. Med. Chem. 39: 3606-3616 (1996).

To the extent that steroid hormone receptors comprise zinc fingers with motifs comprising 4 or 5
5 cysteines, an O²-aryl diazeniumdiolate can be used to modulate steroid hormone activity in an animal, such as a mammal. Accordingly, the present invention also provides a method of modulating steroid hormone activity in an
10 animal, such as a mammal, which is in need of modulation of steroid hormone activity and which comprises a steroid hormone receptor protein comprising a zinc finger that can be inactivated by an O²-aryl diazeniumdiolate. The method comprises administering to the animal, e.g., the mammal, an amount of an O²-aryl diazeniumdiolate
15 sufficient to inactivate the steroid hormone receptor protein so as to modulate steroid hormone activity in the animal.

In yet another embodiment, a method for treating an animal, such as a mammal, for cancer and metastasis
20 thereof is provided. The method comprises administering to the animal, e.g., the mammal, an amount of diazeniumdiolate sufficient to prevent the growth or metastasis of the cancer in the animal.

In one aspect of this embodiment, a method for
25 treating an animal, such as a mammal, for cancer is provided, wherein the cancer is due, at least in part, directly or indirectly, to the activity of a zinc finger protein that can be inactivated by an O²-aryl diazeniumdiolate. The method comprises administering to
30 the animal, e.g., the mammal, an amount of O²-aryl diazeniumdiolate sufficient to inactivate the zinc finger protein so as to treat the cancer in the animal (Rice et al., PNAS 89: 7703-7707 (1992)), i.e., prevent the growth or metastasis of the cancer in the animal.

35 In still yet another embodiment, a method is provided for treating an animal, such as a mammal, for cancer, wherein the cancer is resistant to treatment with

a chemotherapeutic agent (see, e.g., Kelley et al., Biochem. J. 304: 843-848 (1994)), in particular a DNA damaging agent, such as an alkylating agent or an oxidizing agent, due, for example, to the action of an enzyme that adversely affects the activity of the chemotherapeutic agent. The method comprises administering to the animal, e.g., the mammal, an amount of an O²-aryl diazeniumdiolate sufficient to render the cancer in the animal susceptible to treatment with the chemotherapeutic agent. Accordingly, such a method can be used as an adjunct therapy to chemotherapy as needed.

For example, certain O²-aryl diazeniumdiolates can be synthesized to fit into the active site of glutathione S-transferase, specifically isoenzyme π (see, e.g., Ji et al., Biochemistry 32(49): 12949-12954 (1993); and Ji et al., Biochemistry 36: 9690-9702 (1997)). Accordingly, irreversible consumption of glutathione from the active site of glutathione S-transferase- π with an O²-aryl diazeniumdiolate could prevent the enzyme from detoxifying a variety of xenobiotic compounds, such as chemotherapeutic drugs, especially alkylating agents, such as chlorambucil, melphalan and hepsulfam, and other DNA-damaging agents, such as agents that induce electrophilic attack or oxidization, by enzymatic conjugation of the compound with glutathione (see, e.g., Morgan et al., Cancer Chemother. Pharmacol. 37: 363-370 (1996)). This method also has applicability to screening drug-resistant cancer cell lines *in vitro*.

In another embodiment, a method is provided for treating an inanimate object for the presence of a potentially infectious virus, bacterium, or parasite. The method comprises contacting the inanimate object with an amount of a present inventive diazeniumdiolate sufficient to reduce the presence of the potentially infectious virus, bacterium or parasite. By "potentially infectious" is meant the capability of infecting an animal, such as a mammal.

In one aspect of this embodiment, a method is provided for reducing on an inanimate object the presence of a potentially infectious agent, such as a virus, a bacterium, or a parasite, any one of which comprises a zinc finger protein that can be inactivated by an O²-aryl diazeniumdiolate. The method comprises contacting the inanimate object with an amount of an O²-aryl diazeniumdiolate sufficient to inactivate the zinc finger protein so as to reduce the presence of the potentially infectious agent, e.g., virus, bacterium or parasite, on the inanimate object. By "potentially infectious" is meant the capability of infecting an animal, such as a mammal, directly or indirectly.

EXAMPLES

The following examples further illustrate the present invention and, of course, should not be construed as in any way limiting its scope. With respect to the following examples, NO was obtained from Matheson Gas Products (Montgomeryville, PA), β - and α -glycosidases and porcine liver esterase were obtained from Sigma Chemical Co. (St. Louis, MO), polyurethane (Tecoflex) was obtained from Thermedics Inc. (Woburn, MA), and glucose and mannose were obtained from Aldrich Chemical Co. (Milwaukee, WI). Proton NMR spectra were recorded with a 300 MHz Varian Unity Plus or a Varian XL-200 NMR spectrometer. Spectra were obtained in deuteriochloroform for covalent compounds and in D₂O for salts. Chemical shifts are reported in parts per million (ppm) downfield from TMS. Low and high resolution mass spectral (MS) measurements were carried out on a VG-Micromass Model 7070 spectrometer. Unless otherwise indicated, MS data were collected in the electron impact mode with sample introduction via direct probe. Ultraviolet (UV) spectra were run as solutions in water or 0.01 M NaOH on an HP 8451A Diode Array spectrophotometer. Glutathione S-transferase kinetics were monitored by measuring the

change in UV absorbance at 380 nm with a Beckman DU 640 spectrophotometer. Chemiluminescence measurements were done on a Thermal Energy Analyzer Model 502A instrument (Thermedics, Inc., Woburn, MA). Elemental analyses were performed by Atlantic Microlab Inc.

EXAMPLE 1

This Example illustrates the preparation of O^{2-} -(2,4-dinitrophenyl) 1-(N,N-diethylamino)diazene-1-ium-1,2-diolate.

A solution of 1.67 g (11 mmol) of sodium diethylaminodiazoniumdiolate in 20 ml of 5% aqueous sodium bicarbonate was cooled to 0 °C under nitrogen. A solution of 1.3 ml (0.01 mol) of 2,4-dinitrofluorobenzene in 10 ml of t-butyl alcohol was added slowly. A precipitate formed upon addition. The mixture was allowed to warm up to room temperature gradually, then stirred overnight. The product was extracted with dichloromethane and subsequently washed with cold dilute hydrochloric acid followed by sodium bicarbonate solution. The organic layer was dried over sodium sulfate, filtered through a layer of magnesium sulfate, and evaporated under vacuum to give 1.3 g of a red oil, which crystallized on standing. Recrystallization from ethanol gave yellow-orange needles: m.p. 76-7 °C; NMR δ 1.25 (t, 6H), 3.58 (q, 4H), 7.68 (d, 1H), 8.44 (m, 2H), 8.89 (m, 1H); UV (ethanol) $\lambda_{max}(\epsilon)$ 218 (17.4 mM⁻¹ cm⁻¹) and 302 (15.6 mM⁻¹ cm⁻¹) nm; MS, exact mass, calculated for C₁₀H₁₃N₅O₆: (M⁺) 299.0865; measured M⁺ 299.08658. Analysis, C, H, N, calculated for: C₁₀H₁₃N₅O₆: C 40.13%, H 4.35%, N 23.41%. Found: C 40.21%, H 4.43%, N 23.37%.

EXAMPLE 2

This Example illustrates the regeneration of the anionic diazeniumdiolate from its O^{2-} -aryl substituted form (O^{2-} -(2,4-dinitrophenyl) 1-(N,N-diethylamino)diazene-1-ium-1,2-diolate).

A solution of 85 mg (0.28 mmol) of O^2 -(2,4-dinitrophenyl) 1-(N,N-diethylamino)diazene-1-ium-1,2-diolate, prepared as in Example 1, in 1 ml of ether was cooled to -4°C and treated with 1 ml of diethylamine.

5 The solution was kept at -4°C for 1 hr, giving a precipitate. The solid was collected by filtration. The filtrate was concentrated and analyzed by NMR; the residue proved to be identical to an authentic sample of 2,4-dinitro-N,N-diethylaniline. The precipitate was

10 washed with petroleum ether and dried under N_2 to give 5.4 mg of product having λ_{max} 250 nm; NMR (D_2O) δ 0.96 (t, 6H), 1.28 (t, 6H), 2.94 (q, 4H), 3.08 (q, 4H). This product proved to be identical to an authentic sample of diethylammonium 1-(N,N-diethylamino)diazene-1-ium-1,2-

15 diolate.

EXAMPLE 3

This Example illustrates the chemical cleavage of the O^2 -aryl bond of an O^2 -aryl diazeniumdiolate mediated

20 by sodium methoxide.

A solution of 16 mg (0.064 mmol) of O^2 -(2,4-dinitrophenyl) 1-(N,N-diethylamino)diazene-1-ium-1,2-diolate in 1 ml of ether was treated with 29 μl of 25% sodium methoxide in methanol (0.14 mmol) and allowed to

25 stand at -4°C for 2 hr. The solid precipitate was collected by filtration, washed with ether and dried under vacuum to yield 4 mg of a solid identical to an authentic sample of 1-(N,N-diethylamino)diazene-1-ium-1,2-diolate sodium salt.

30

EXAMPLE 4

This Example illustrates the kinetics of reaction of O^2 -(2,4-dinitrophenyl) 1-(N,N-diethylamino)diazene-1-ium-1,2-diolate with sodium methoxide in methanol. The

35 kinetics of this reaction show the rate of conversion of O^2 -(2,4-dinitrophenyl) 1-(N,N-diethylamino)diazene-1-ium-1,2-diolate to 1-(N,N-diethylamino)diazene-1-ium-1,2-

diolate ion in alkaline or nucleophilic environments.

An excess of NaOMe was used in the reactions; aliquots were collected at intervals and quenched with 0.1 N HCl in methanol. The disappearance of $O^2-(2,4-$
5 $dinitrophenyl) 1-(N,N-diethylamino)diazen-1-ium-1,2-$
diolate, monitored by HPLC, was found to fit the first-order rate equation. This was determined by plotting $\log[O^2-(2,4-dinitrophenyl) 1-(N,N-diethylamino)diazen-1-$
10 $ium-1,2-diolate]$ vs. time to find k_{obs} , at four different concentrations of NaOMe. Similarly, the second-order rate constant ($7.87 M^{-1} min^{-1}$) was determined by plotting $\log k_{obs}$ vs. $\log[NaOMe]$.

EXAMPLE 5

15 This Example illustrates the preparation of $O^2-(2,4-dinitrophenyl) 1-(N-isopropylamino)diazen-1-ium-1,2-$
diolate.

A solution of 84 mg (0.597 mmol) of sodium 1-(N-isopropylamino)diazen-1-ium-1,2-diolate in 1 ml of 5%
20 sodium bicarbonate was cooled to 0 °C and 69 mg (0.55 mmol) of 2,4-dinitrofluorobenzene was added. The ice bath was removed, the mixture was allowed to stir at room temperature overnight, and then the mixture was extracted with dichloromethane. The extract was dried over sodium
25 sulfate, filtered and evaporated in vacuo to give 86 mg of a film, which crystallized on standing: m.p. 92-93 °C
NMR δ 1.39 (d, 6H), 3.99 (septet, 1H), 6.93 (d, 1 H), 8.27 (dd, 1H), 8.5 (b, 1H), 9.15 (d, 1H).

30 EXAMPLE 6

This Example illustrates the synthesis of pyrrolidinium 1-[pyrrolidin-1-yl]diazen-1-ium-1,2-diolate.

A solution of 36 g (0.507 mol) of pyrrolidine in 50
35 ml of ether and 25 ml of acetonitrile was placed in a 500 ml Parr bottle, degassed and charged with 40 psi of nitric oxide. The reactor was cooled to -80 °C. The

pressure was maintained at 40 psi. After 4 hr, the pressure was released, and the crystalline product was collected by filtration in a fritted glass funnel and then washed with cold ether under an atmosphere of nitrogen. The material was dried in a vacuum desiccator at 1 mm Hg and 25 °C for 3 hr to give 23 g (45%) of white needles: m.p. 68-70 °C. Analysis C,H,N: Calculated for $C_8H_{18}N_4O_2$: C 47.51%, H 8.97%, N 27.70%; Found, C 47.62%, H 9.04%, N 27.46%.

The pyrrolidinium salt was converted to the more stable sodium salt for subsequent O^2 -arylations by treatment with 10 N NaOH to promote cation exchange. It was then flooded with ether. The product was collected by filtration.

EXAMPLE 7

This Example gives an alternate method of preparing the sodium salt of the 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate presented in Example 6.

A solution of 28.2 g (0.397 mol) of pyrrolidine in 100 ml of acetonitrile and 100 ml of ether was mixed with 94 ml (0.4 mol) of 25% sodium methoxide in methanol. The resulting solution was flushed with nitrogen then charged with 40 psi of NO and stirred at room temperature for two days forming a thick precipitate. (The precipitate had begun to form within 1 hr of exposure to NO.) The pressure was released and the product was collected by filtration. The product was washed with ether and dried under vacuum to give 32.1 g (54%) of a white powder: UV (0.01 N NaOH) λ_{max} (ϵ), 252 nm ($8.84 \text{ mM}^{-1} \text{ cm}^{-1}$); $t_{1/2}$ 8.5 sec at 25 °C and 2.8 sec at 37 °C in pH 7.4 phosphate buffer; NMR (D_2O) δ 1.91 (m, 4H) , 3.22 (m, 4H).

EXAMPLE 8

This Example illustrates the preparation of O^2 -(2,4-dinitrophenyl) 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate.

A solution of 556 mg (3.63 mmol) of sodium 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate in 10 ml of 5% aqueous sodium bicarbonate was cooled to 0 °C. A solution of 456 μ l (3.63 mmol) of 2,4-dinitrofluorobenzene in 2 ml of t-butyl alcohol was added and the resulting mixture was stirred at room temperature overnight. The yellow-orange precipitate was collected by filtration, washed with water, and dried to give 758 mg of product, which was recrystallized from ethanol: m.p. 94-95 °C; NMR, δ 2.04 (m, 4H), 3.35 (m, 4H), 6.90 (d, 1H), 8.20 (dd, 1H), 8.67 (d, 1H); MS, m/z(%), 297 (M^+ , 1), 220 (100), 237 (30), 190 (94), 180 (15), 162 (10), 149 (26), 130 (20), 100 (95), 70 (24), 63 (35), 56 (18). Exact Mass: calculated for $C_{10}H_{11}N_5O_6$ (M^+) 297.0708; measured 297.0709.

EXAMPLE 9

This Example illustrates the preparation of sodium 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate.

A solution of 20 g (0.126 mol) of N-carboethoxypiperazine in 60 ml of methanol was placed in a Parr bottle. The solution was treated with 27.4 ml (0.126 mol) of 25% sodium methoxide in methanol; the system was evacuated, charged with 40 psi of nitric oxide and kept at 25 °C for 48 hr. The white crystalline product was collected by filtration and washed with cold methanol as well as with copious amounts of ether. The product was dried under vacuum to give a 14.5 g (48%) yield of sodium 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate: m.p. 184-5 °C; UV (0.01 N NaOH) λ_{max} (ϵ) 252 nm ($10.4 \text{ mM}^{-1} \text{ cm}^{-1}$); NMR (D_2O) δ 1.25 (t, 3H), 2.15 (q, 2H) 3.11 (m, 4H), 3.68 (m, 4H). Anal calcd. for $C_6H_{13}N_4O_4Na$: C 35.00%, H 5.42%, N 23.33%, Na 9.58%. Found: C 34.87%, H 5.53%, N 23.26%, Na 9.69%.

The half-life of this compound at pH 7 and 25 °C was

assessed at 5 min. This measurement was based on the loss of the 252 nm chromophore in the ultraviolet spectrum.

5 EXAMPLE 10

This Example illustrates the preparation of O^2 -(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazene-1-ium-1,2-diolate.

A solution of 1.073 g (0.0045 mol) of sodium 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazene-1-ium-1,2-diolate in 10 ml of 5% sodium bicarbonate was cooled at 0 °C under nitrogen. A partial solution of 0.89 ml (0.0044 mol) of 2,4-dinitrofluorobenzene in 10 ml of t-butyl alcohol was added. A precipitate formed upon addition; the mixture 15 was allowed to stir at room temperature for 4 hr. The product was extracted with dichloromethane. The extracts were washed with water, dried over sodium sulfate and filtered through a layer of anhydrous magnesium sulfate. Evaporation of the solvent gave an orange glass which 20 crystallized on standing. The product was recrystallized from ethanol:dichloromethane to give 1.3 g (76%) of analytically pure material: m.p. 140-141 °C; NMR δ 1.32 (t, 3H), 3.63 (m, 4H), 3.74 (m, 4H), 4.19 (q, 2H), 7.66 (d, 1 H), 8.48 (q, 1H), 8.88 (d, 1 H); UV (H₂O) λ_{\max} (ϵ) 210 nm (13.3 mM⁻¹ cm⁻¹), 300 nm (12 mM⁻¹ cm⁻¹). Anal calcd. 25 for C₁₃H₁₆N₆O₈: C 40.61%, H 4.20%, N 21.87%; Found: C 40.74%, H 4.13%, N 21.98%.

EXAMPLE 11

30 This Example illustrates the preparation of O^2 -(2-chloropyrimidin-4-yl) 1-(N,N-diethylamino)diazene-1-ium-1,2-diolate.

A solution of 600 mg (4 mmol) of 2,4-dichloropyrimidine in 2 ml of dimethylsulfoxide and 5 ml 35 of tetrahydrofuran was added via syringe to a slurry of 678 mg (4.37 mmol) of sodium 1-(N,N-diethylamino)diazene-1-ium-1,2-diolate in 5 ml of tetrahydrofuran at room

temperature under nitrogen and the resulting mixture was stirred for 72 hr. Five (5) ml of ether was added to the mixture. After washing with water, the organic layer was dried over sodium sulfate, filtered through a layer of magnesium sulfate, and evaporated to give 679 mg of an oil which crystallized at -20°C . This material was recrystallized from ether-petroleum ether: m.p. $37-38^{\circ}\text{C}$; NMR δ 1.25 (t, 6H), 3.56 (q, 4H), 7.00 (d, 1H), 8.50 (d, 1H); UV, λ_{max} (ϵ) 268 nm ($9.3 \text{ mM}^{-1} \text{ cm}^{-1}$). Analysis C, H, N: Calculated for $\text{C}_8\text{H}_{12}\text{N}_5\text{O}_2\text{Cl}$: 39.11%, H 4.92%, N 28.51%, Cl 14.43%; Found: C 38.96%, H 4.96%, N 28.35%, Cl 14.60%.

EXAMPLE 12


This Example illustrates the preparation of 2-(2-chloropyrimidin-1-yl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazene-1,2-diolate.

A solution of 262 mg (1.76 mmol) of 2,4-dichloropyrimidine in 3 ml of dimethylsulfoxide was added to a slurry of 424 mg (1.76 mmol) of sodium 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazene-1,2-diolate in 10 ml of tetrahydrofuran at room temperature under nitrogen and stirred for 72 hr. The resulting homogeneous solution was treated with 100 ml of water. The precipitate was collected by filtration and dried under vacuum to give 300 mg of product: m.p. $136-137^{\circ}\text{C}$; NMR δ 1.29 (t, 3H), 3.69 (m, 4H), 3.71 (m, 4H), 4.18 (q, 2 H), 6.99 (d, 1 H), 8.52 (d, 1 H); (UV) λ_{max} (ϵ) 270 nm ($4.1 \text{ mM}^{-1} \text{ cm}^{-1}$).


This compound undergoes nucleophilic substitution with methoxide to displace the chlorine atom at the C2 position and the diazeniumdiolate at the C4 position to give 2,4-dimethoxypyrimidine.

EXAMPLE 13

This Example describes the synthesis of the following compounds:




1




2

5




3



4

10



5

15

General synthesis of compounds 1 through 5: A 1 M solution of sodium 1-(N,N-diethylamino)diazene-1,2-diolate in dimethylsulfoxide was stirred at 5 °C under nitrogen. A 1 M solution containing 0.95 molar equivalents of the arylating agent in tetrahydrofuran was injected through a septum. The reaction mixture was allowed to warm up to room temperature, stirred overnight, quenched with ice-water and extracted with ether. The ether was washed with water, dried over sodium sulfate, filtered through a layer of magnesium sulfate and concentrated on a rotary evaporator. The methods of purification varied with each preparation and are described with the individual compounds below. (Note: Compounds 1 through 5 are selected products from O²-aryl compound libraries built

using solution phase synthetic methods in parallel fashion). NMR spectra were run in CDCl_3 .

5 O^2 -(2-Nitro-4-trifluoromethylphenyl) 1-(N,N-diethylamino)diazen-1-ium-1,2-diolate, 1: Arylation was carried out with 4-fluoro-3-nitrobenzotrifluoride. Purification of the product was carried out on preparative HPLC using a 1 inch C-18 column eluted with 20% aqueous acetonitrile with a solvent gradient to 50%
10 acetonitrile:50% water. A 42% yield of product was obtained as an oil: NMR δ 1.23 (t, 6H), 3.50 (q, 4 H), 7.66 (d, 1 H), 7.82 (d, 1 H), 8.28 (s, 1 H).

15 O^2 -(2-Nitro-4-carboxylatophenyl) 1-(N,N-diethylamino)diazen-1-ium-1,2-diolate, 2: 4-Fluoro-3-nitrobenzoic acid was used in this preparation. Purification of the product was carried out on a Biotage Flash 40 system with a 4.0 x 15.0 cm KP-Sil column. The system was eluted with 5:1
20 dichloromethane:ethyl acetate at 15 psi of air at a rate of elution of 25 ml/min to give a 22% yield of product: mp 115-6 °C; NMR δ 1.22 (t, 6 H), 3.33 (q, 4 H), 7.06 (d, 1 H), 8.03 (dd, 1 H), 8.37 (m, 1 H).

25 O^2 -(5-Nitropyrid-2-yl)1-(N,N-diethyl)diazen-1-ium-1,2-diolate, 3: The product of reaction with 2-bromo-5-nitropyridine was recrystallized from ether:ethanol to give pure 3 in 62% yield: mp 77-8 °C; NMR δ 1.24 (t, 6 H), 3.53 (q, 4 H), 7.21 (dd, 1 H), 8.52 (dd, 1 H), 9.17
30 (dd, 1 H). Analysis C,H,N: Calculated for $\text{C}_9\text{H}_{13}\text{N}_5\text{O}_4$: C 42.35%, H 5.13%, N 27.44%, Found: C 42.46%, H 5.14%, N 27.52%.

35 O^2 -(3,5-Dinitropyrid-2-yl)1-(N,N-diethyl)diazen-1-ium-1,2-diolate, 4: Anylation was effected with 2-chloro-3,5-dinitropyridine as described in the general procedure. The crude product was recrystallized from ether:petroleum

ether to give 4 in 33% yield: mp 56-7 °C; NMR δ 1.28 (t, 6 H), 3.57 (q, 4 H), 8.81 (d, 1 H), 9.10 (d, 1 H).

O²-(3-Nitropyrid-2-yl)-1-(N,N-diethyl)diazen-1-ium-1,2-
5 diolate, 5: 2-Chloro-3-nitropyridine was used in this reaction. The crude product was purified on a Flash 40 system using a 4.0 x 7.0 cm KP-Sil column eluted with 100% dichloromethane to give a 52% yield of product as a viscous oil: NMR δ 1.25 (t, 6 H), 3.55 (q, 4 H), 7.26
10 (m, 1 H), 8.48 (m, 2 H).

EXAMPLE 14

This Example illustrates the preparation of O²-vinyl
15 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-
diolate(V-PROLI/NO).

To 3.56 g (9.2 mmol) of O²-(2-bromoethyl) 1-[(2-
carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolate 2-
bromoethyl ester was added 10 ml of 10 N sodium hydroxide
20 solution.

The two-phase mixture was stirred at 25 °C,
whereupon the compound gradually dissolved in the aqueous
layer. After stirring overnight, the UV of the reaction
mixture exhibited an absorption maximum at 266 nm
25 (starting material absorbed at 252 nm), indicating the
formation of a vinyl group.

The solution was cooled to 0 °C and carefully
acidified to pH 4 by the slow addition of 10%
hydrochloric acid. Care must be taken to keep the
30 solution cold while acid is added. The acidic solution
was extracted with ethyl acetate, dried over sodium
sulfate and filtered through a layer of magnesium
sulfate. Evaporation of the solvent gave 1.4 g of an
oil. Purification was carried out on a Flash 40 System
35 (Biotage) using a 4.0 x 7.0 cm KP-Sil column and 2:1
ethyl acetate:cyclohexane as the eluant:ir (film) 3163,
2987, 1734, 1630, 1490 cm⁻¹; NMR (CDCl₃) δ 2.06-2.3

(m, 4H), 3.62 (m, 2H), 4.47 (q, 1H), 4.77 (ABq, 1H), 5.02 (ABq, 1H), 6.75 (q, 1H); UV λ_{max} (ϵ) 266 nm ($6.3 \text{ mM}^{-1} \text{ cm}^{-1}$); MS, m/z (%) 201 (M^+ , 5), 176 (10), 150 (49), 145 (27), 114 (9), 99 (45), 70 (99.9), 69 (57), 68 (45).


5

EXAMPLE 15

This Example illustrates the regeneration of NO from O^2 -(2,4-dinitrophenyl) 1-(N,N-diethylamino)diazen-1-ium-1,2-diolate in the presence, but not the absence, of glutathione.

10 A solution containing 1 mM glutathione (GSH) in 10 mM phosphate buffer was degassed by purging with argon for 10 min, whereupon a 3 ml aliquot was mixed with 3 μ l of a dioxane solution that was 2 mM in O^2 -(2,4-
15 dinitrophenyl) 1-(N,N-diethylamino)diazen-1-ium-1,2-diolate. NO release was monitored by chemiluminescence while the mixture was held at 37 °C. After a brief lag time, peak nitric oxide generation was observed at approximately 15 minutes after the reaction was initiated
20 and continued at readily detectable levels for approximately 100 minutes. Total NO generation during the first 112 min was approximately 9 nmol. Assuming that 2 nmol of NO is generated per mol of O^2 -(2,4-dinitrophenyl) 1-(N,N-diethylamino)diazen-1-ium-1,2-diolate, this 9 nmol corresponds to roughly 75% of the
25 theoretical yield.

When the reaction was repeated as above but with exclusion of the GSH, no NO generation was observed. The nucleophilic glutathione reacted with the O^2 -(2,4-
30 dinitrophenyl) 1-(N,N-diethylamino)diazen-1-ium-1,2-diolate to produce NO according to the equation shown below.



This example is illustrative of the ability of some of the O^2 -aryl diazeniumdiolate compounds of the present invention to undergo nucleophilic substitution by
 5 nucleophilic side-chains of amino acids such as cysteine, which are often found in the active sites of enzymes. The result of such nucleophilic substitution is the generation of an aryl derivative of the displacing amino acid residue and a diazeniumdiolate capable of producing
 10 NO, through a predictable, first-order reaction.

O^2 -(2,4-Dinitrophenyl) 1-(N,N-diethylamino)diazen-1-ium-1,2-diolate and glutathione were also assayed in the presence and absence of glutathione S-transferase. Assays were conducted in a thermostated cell compartment
 15 at 25 °C, using 0.1 M phosphate buffer at pH 7.4, with a final volume of 3 ml. The concentration of the enzyme was 0.7 µg/ml, whereas that of glutathione was 1.4 mM. The concentration of diazeniumdiolate was varied from 50-100 µM. Using the integrated form of the Henri-
 20 Michaelis-Menten equation, K_m was found to be 46.3 µM and V_{max} was found to be 0.89 µM min⁻¹.

EXAMPLE 16

This Example illustrates a route of synthesis which
 25 is useful in the production of diazeniumdiolated nucleotides, nucleosides, and nucleic acids and further

illustrates a route to synthesis of O²-aryl diazeniumdiolates, which comprises converting an amino group to a diazonium group, followed by reaction of the diazonium group with a diazeniumdiolate.

5 2'-Deoxycytidine is reacted with nitric oxide in the presence of a suitable 1-electron oxidant which results in the conversion of the amino group of the cytidine into a diazonium group while reducing the oxidant and producing hydroxide ion. The resulting diazotized (i.e.,
10 diazonium derivatized) pyrimidine is then reacted with 1-(N,N-diethylamino)diazen-1-ium-1,2-diolate ion, as described in the previous examples, to generate a diazeniumdiolated 2'-deoxyuridine derivative. This diazeniumdiolated 2'-deoxyuridine derivative can be
15 reacted with strong nucleophiles (e.g., hydroxide ions). This will result in the regeneration of 1-(N,N-diethylamino)diazen-1-ium-1,2-diolate ion plus 2'-deoxyuridine. This regenerated 1-(N,N-diethylamino)diazen-1-ium-1,2-diolate ion will generate
20 NO in a predictable, first-order reaction. This Example demonstrates a basis for a mechanism that is suitable for targeting nitric oxide to a particular site of a mammalian body, so that the specificity of NO action can be increased.

25

EXAMPLE 17

This example demonstrates the ability of an O²-aryl diazeniumdiolate to inactivate a zinc finger protein by zinc ejection.

30

Samples of recombinant nucleocapsid protein p7 (p7NC) from HIV-1 (L.O. Arthur, AIDS Vaccine Program, NCI-FCRDC, Frederick, MD) were prepared at µg/ml in 10 mM sodium phosphate buffer (pH = 7.0) and treated with 25 µmol of an O²-aryl diazeniumdiolate in a total volume of
35 1.0 ml. At various time intervals, as shown in Figure 1, which is a graph of Trp37 fluorescence (RFU) versus time (min), the samples were diluted 1/10 in 10 mM sodium

phosphate buffer (pH = 7.0) to prevent introduction of any artifactual quenching effects and the fluorescence intensity of the tryptophan residue (Trp37) in the C-terminal zinc finger of p7NC in each sample was
5 determined as previously described (Rice et al., Int. Antiviral News 3: 87-89 (1995)). The excitation and emission wavelengths utilized with a Shimadzu RF5000 spectrofluorimeter were 280 and 351 nm, respectively. The results are shown in Figure 1, in which ○ represents
10 the negative control, i.e., no drug, □ represents the positive control, i.e., 642151 (see Rice et al. (1997), *supra*), ■ represents the compound of Example 1 (LK1), ♦ represents the compound of Example 8 (LK2), ▲ represents the compound of Example 5 (LK3), • represents the
15 compound of Example 10 (LK4), and × represents the compound of Example 11 (LK5). The results indicate that an O²-aryl diazeniumdiolate can eject zinc from a zinc finger protein.

20 EXAMPLE 18

This example demonstrates the anti-HIV activity of O²-aryl diazeniumdiolates.

The tumor cell line of T4 lymphocytes designated CEM-SS was grown in a synthetic medium with fetal bovine
25 serum (Rice et al., Advances in Pharmacol. 33: 389-438 (1995)). O²-aryl diazeniumdiolates were administered to HIV-1-infected and uninfected CEM-SS cells at concentrations ranging from 10^{-3.5} to 10^{-7.0} M in accordance with the XTT-based cell viability assay of the National
30 Cancer Institute (see, e.g., Rice et al. (1995), *supra*).

After exposure of CEM-SS cells to the compounds, the percentage of T-cell viability was assessed. The viability of HIV-1-infected CEM-SS cells, which were contacted with a subtoxic concentration of any one of the
35 above-described O²-aryl diazeniumdiolates, was substantially increased in comparison to untreated cells.

Compounds 1-3 from Example 13 were especially effective.

EXAMPLE 19

This example describes the preparation of disodium
5 1-[(2-carboxylato)pyrrolidin-1-yl]diazene-1-ium-1,2-
diolate.

A solution of 10 g (0.087 mol) of L-proline in 39 ml
(0.18 mol) of 25% sodium methoxide in methanol, 20 ml of
methanol and 40 ml of ether was degassed and exposed to
10 40 psi of nitric oxide for 20 hr. The pressure was
released and the solid residue was collected by
filtration, washed with ether and dried under vacuum to
give 17 g of a white solid: mp 250 °C (dec.); UV (0.01 N
NaOH) λ_{max} (ϵ) 252 nm ($8.4 \text{ mM}^{-1} \text{ cm}^{-1}$); NMR (D_2O) δ 1.71 (m,
15 1H), 1.91 (m, 2H), 2.27 (m, 1H), 3.27-3.43 (m, 2H), 4.04
(m, 1H) (a methanol singlet at 3.34 is also observed); ^{13}C
NMR, 24.45 ppm, 30.97, 48.73 (methanol), 54.95, 67.70,
182.75.

Anal. C,H,N: Calculated for $\text{C}_5\text{H}_7\text{N}_3\text{O}_4\text{Na}_2 \cdot \text{CH}_3\text{OH}$, C
20 28.69%, H 4.41%, N 16.73%, Na 18.30%; Found C 28.65%, H
3.99%, N 16.74%, Na 18.04%.

EXAMPLE 20

This example describes the preparation of O²-methyl
25 1-[(2-carboxylato)pyrrolidin-1-yl]diazene-1-ium-1,2-
diolate methyl ester.

Disodium 1-[(2-carboxylato)pyrrolidin-1-yl]diazene-1-
ium-1,2-diolate (methanol solvate, FW 251; 6.8 g; 0.027
mol) was placed in a 300 ml 3-neck flask and cooled to
30 -20 °C. Cold methanol (-20 °C; 200 ml) was added to the
solid while stirring to give a homogeneous solution,
which was cooled further to -35 °C. A solution of 9.5 ml
(0.1 mol) of dimethylsulfate in 25 ml of ether was added
dropwise over a 15 min period. The reaction mixture was
35 then allowed to warm to room temperature gradually and
stirred for an additional 4 hr. The progress of the
reaction was monitored on silica gel TLC using 10:1

dichloromethane:ethyl acetate as the eluant. The reaction mixture was filtered, the methanol was removed on a rotary evaporator, and the residue was extracted with dichloromethane. The solution was washed with aqueous sodium bicarbonate, dried over sodium sulfate and filtered through a layer of magnesium sulfate. Evaporation of the solvent gave an oil, which crystallized on standing. Recrystallization from ether:petroleum ether gave 945 mg (18%) of an analytically pure sample: mp 62-63 °C; UV (0.01 N NaOH), λ_{\max} (ϵ) 252 nm ($6.79 \text{ mM}^{-1} \text{ cm}^{-1}$); NMR δ 2.05 (m, 3H), 2.30 (m, 1H), 3.65 (m, 1H), 3.75 (s, 3H), 3.83 (m, 1H), 3.96 (s, 3H), 4.55 (m, 1H); MS m/z (%) 203 (M^+ , 6), 188 (20), 58 (35), 120 (22), 99 (100), 95 (34), 69 (36), 59 (24); exact mass calculated for $C_7H_{13}N_3O_4$ (M^+) 203.0906, found (M^+) 203.0906.

Anal. C,H,N: Calculated for $C_7H_{13}N_3O_4$, C 41.38%, H 6.45%, N 20.68%; Found C 41.48%, H 6.43%, N 20.59%.

EXAMPLE 21

This example describes the preparation of O^2 -(N,N-dimethylsulfamoyl) 1-[(2-carboxylato)pyrrolidin-1-yl]diazene-1-ium-1,2-diolate.

A solution of 1.08 ml (0.01 mol) of N,N-dimethylsulfamoyl chloride in 5 ml of tetrahydrofuran was added dropwise to a cold (0 °C) solution of 1.57 g (0.0062 mol) of disodium 1-[(2-carboxylato)pyrrolidin-1-yl]diazene-1-ium-1,2-diolate in 25 ml of 0.1 N NaOH in saline solution. The reaction mixture was allowed to warm up to room temperature and stirred overnight. The aqueous layer was extracted with dichloromethane and the organic layer was dried over anhydrous sodium sulfate. The aqueous layer showed no significant UV absorption after extraction and, thus, indicated that the extraction products were devoid of diazeniumdiolate. The organic layer was filtered through a layer of magnesium sulfate and the solvent was

removed on a rotary evaporator to give 989 mg of a pale yellow oil, which was chromatographed on silica gel using 5:1 dichloromethane:ethyl acetate as the eluant. The fractions containing the desired product were combined and concentrated under vacuum to give a solid, which was recrystallized from ether-petroleum ether: mp 97-98 °C; UV (0.01 N NaOH) λ_{\max} (ϵ) 266 nm ($8.05 \text{ mM}^{-1} \text{ cm}^{-1}$); NMR δ 2.16 (m, 3H), 2.40 (m, 1H), 3.01 (s, 6H), 3.83 (m, 1H), 3.94 (m, 1H), 4.69 (q, 1H), 6.80 (b, 1H).

Anal. C,H,N,S: Calculated for $\text{C}_7\text{H}_{14}\text{N}_4\text{SO}_6$, C 29.79%, H 5.00%, N 19.85%, S 11.36%; Found C 29.93%, H 5.09%, N 19.76%, S 11.27%.

EXAMPLE 22

This example describes the preparation of O^2 -methoxymethyl 1-[(2-carboxylato)pyrrolidin-1-yl]diazene-1-ium-1,2-diolate methoxymethyl ester.

A slurry of 485 mg (1.93 mmol) of disodium 1-[(2-carboxylato)pyrrolidin-1-yl]diazene-1-ium-1,2-diolate in 20 ml of anhydrous tetrahydrofuran was cooled to 0 °C under a nitrogen atmosphere. Triethylamine (0.5 ml) was added to the cold solution followed by the slow addition of 360 mg (4.45 mmol) of chloromethylmethyl ether and a subsequent dropwise addition of 0.5 ml of methanol. The solution was then stirred in the cold for 1.5 hr. The reaction mixture was allowed to warm up to room temperature and stirred under nitrogen for an additional 1.5 hr. The reaction was quenched with crushed ice, whereupon the solvent was removed on a rotary evaporator and the residue was extracted with dichloromethane. The organic phase was washed with water, dried over sodium sulfate, filtered through magnesium sulfate and evaporated *in vacuo* to give 330 mg of a yellow oil, which was purified on a silica gel column with 5:1 dichloromethane:ethyl acetate as the eluant: UV (H_2O) λ_{\max} (ϵ) 250 nm ($8.58 \text{ mM}^{-1} \text{ cm}^{-1}$); NMR δ 2.09 (m, 3H), 2.35 (m,

1H), 3.48 (s, H), 3.71 (m, 2H), 3.90 (m, 1H), 4.61 (dd, 1H), 5.17 (ab q, 2H), 5.31 (ab q, 2H).

Anal. C,H,N: Calculated for $C_9H_{17}N_3O_6$: C 41.06%, H 6.51%, N 15.96 %: Found C 40.87%, H 6.53%, N 15.76%.

5

EXAMPLE 23

This example describes the preparation of O^2 -(2-bromoethyl) 1-[(2-carboxylato)pyrrolidin-1-yl]diazene-1-ium-1,2-diolate 2-bromoethyl ester.

10 A solution of 20 ml (0.28 mol) of bromoethanol in 50 ml of dichloromethane was cooled to 0 °C and 11.25 ml (0.28 mol) of sulfonyl chloride in 50 ml of dichloromethane was added dropwise to the solution. The resulting solution was kept at 4 °C for 72 hr. The
15 solution was washed with cold 10% NaOH until the washings tested distinctly basic. The organic layer was dried over sodium sulfate, filtered through a layer of magnesium sulfate and concentrated on a rotary evaporator. The resulting crude product (2-
20 bromoethoxysulfonyl chloride, $BrCH_2CH_2OSO_2Cl$) was vacuum-distilled to give 35 g (56%) of a colorless oil: bp 73-75 °C at 1.5 mmHg; NMR δ 3.64 (t, 2H), 4.752 (t, 2H); MS m/z (%) 221 (M^+ , 1), 143 (10), 129 (25), 106 (100), 93 (62). Analysis C,H,N,S,X: Calculated for $C_2H_4SO_3ClBr$:
25 C 10.75%, H 1.80%, S 14.35%, total halogen as Br 71.52% and as Cl 31.72%; Found: C 10.82% H 1.80%, S 14.35%, total halogen as Br 71.63% and as Cl 31.78%.

Disodium 1-[(2-carboxylato)pyrrolidin-1-yl]diazene-1-ium-1,2-diolate (4.86 g; 0.0194 mol) was placed in a 100
30 ml round-bottom flask, together with 2.2 g of anhydrous sodium carbonate. The flask was immersed in a dry ice-acetonitrile bath (at -40 °C) and 50 ml of cold (-20 °C) ethanol was added. Then the mixture was stirred and allowed to stabilize at -40 °C under an atmosphere of
35 nitrogen. To the cold slurry was added, via a syringe, 9.45 g (0.0422 mol) of 2-bromoethoxysulfonyl chloride over a period of 10 min. After stirring for 2 hr, the

reaction mixture was allowed to warm to 15 °C and stirred for an additional 2 hr. The reaction mixture was poured into 250 ml of ice-water and extracted with dichloromethane. The organic layer was washed with aqueous sodium bisulfite solution, dried over sodium sulfate and filtered through a layer of magnesium sulfate, whereupon the solvent was removed on a rotary evaporator. The crude product was chromatographed on a silica gel column using 1:1 cyclohexane:ethyl acetate as the eluant to give 2.7 g (36%) of a pale yellow oil: NMR δ 2.11 (m, 3H), 2.35 (m, 1H), 3.55 (m, 4H), 3.68 (m, 1H), 3.86 (m, 1H), 4.46 (m, 4H), 4.59 (m, 1H); UV (H^2O) λ_{max} (ϵ) 252 nm ($6.6 \text{ mM}^{-1} \text{ cm}^{-1}$).

EXAMPLE 24

This example describes the preparation of O^2 -[S-acetyl-(2-mercaptoethyl)] 1-[(2-carboxylato)pyrrolidin-1-yl]diazene-1-ium-1,2-diolate [S-acetyl-(2-mercaptoethyl)] ester.

1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) (1.03 g; 0.0068 mol) was added to a solution of 1.33 g (0.0034 mol) of O^2 -(2-bromoethyl) 1-[(2-carboxylato)pyrrolidin-1-yl]diazene-1-ium-1,2-diolate 2-bromoethyl ester in 35 ml of tetrahydrofuran and the resulting solution was stirred at room temperature under nitrogen. Two equivalents of thiolacetic acid (0.479 ml, 0.0068 mol) were added and the mixture was stirred at room temperature for 2 hr. The mixture was filtered and the solid residue was washed with ether. The filtrate was evaporated to dryness under reduced pressure and the residue was extracted with methylene chloride. The organic solution was subsequently washed with ice-cold 5 N HCl, sodium bicarbonate solution and water. The solution was dried over sodium sulfate, filtered through a layer of magnesium sulfate and evaporated *in vacuo* to give 710 mg of a yellow oil. Chromatography was carried out on a silica gel column eluted with 1:1 cyclohexane:ethyl

acetate: UV (H₂O) λ_{\max} (ϵ) 232 nm (7.0 mM⁻¹ cm⁻¹); NMR δ 2.09 (m, 3H), 2.36 (m, 1H), 2.38 (s, 6H), 3.09 (m, 4H), 3.78 (m, 2H), 4.27 (m, 4H), 4.55 (m, 1H).

5 EXAMPLE 25

This example describes the determination of the halflife of the compound produced in Example 24 in the absence and presence of porcine liver esterase at 25 °C and pH 7.4.

10 A 0.009 M ethanolic stock solution of O²-[S-acetyl-(2-mercaptoethyl)] 1-[(2-carboxylato)pyrrolidin-1-yl]diazene-1-ium-1,2-diolate [S-acetyl-(2-mercapto-ethyl)] ester was prepared. The decay of this compound was monitored at 25 °C as 1.5 x 10⁻⁴ M solutions in a 4 ml
15 quartz cuvette containing 3 ml of phosphate buffer (pH 7.4) and 50 ml of stock solution. The decay of the 232 nm chromophore was monitored on the ultraviolet spectrophotometer. The halflife was estimated as 3.2 hr.

A second set of experiments was carried out using
20 the above parameters to measure the decay after addition of 5 ml of porcine liver esterase suspension. The halflife for the esterase reaction was 8 min at 25 °C.

EXAMPLE 26

25 This example describes the preparation of a nitric oxide-releasing polymer blend of O²-[S-acetyl-(2-mercaptoethyl)] 1-[(2-carboxylato)pyrrolidin-1-yl]diazene-1-ium-1,2-diolate [S-acetyl-(2-mercaptoethyl)] ester.

A solution of 50 mg (0.132 mmol) of O²-[S-acetyl-(2-mercaptoethyl)] 1-[(2-carboxylato)pyrrolidin-1-yl]diazene-1-ium-1,2-diolate [S-acetyl-(2-mercaptoethyl)] ester in 1
30 ml of tetrahydrofuran was dissolved in a solution of 498 mg of polyurethane in 10 ml of tetrahydrofuran. The homogeneous lacquer was concentrated under a stream of
dry nitrogen followed by further drying under high vacuum
35 to give a solid, which contained 0.091 mg (0.24 mmol) of O²-[S-acetyl-(2-mercaptoethyl)] 1-[(2-

carboxylato)pyrrolidin-1-yl]diazene-1-ium-1,2-diolate [S-acetyl-(2-mercaptoethyl)] ester per mg of polymer composite. Rates of NO release were measured as a function of time after immersing a 32 mg aliquot of the diazeniumdiolate in 2 ml of phosphate buffer, pH 7.4, at 37 °C, with a chemiluminescence detector. A set of experiments was carried out in plain buffer, while another set was done in the presence of porcine liver esterase. A very small amount of NO was released in the absence of enzyme over a 200 hr period, while a significant rate of NO production was observed when the enzyme was present in the buffer. This indicates that as the diazeniumdiolate oozes out of the polymer composite, it is hydrolyzed by the enzyme with further cleavage to NO.

EXAMPLE 27

This example describes the introduction of the nitric oxide-releasing O²-[S-acetyl-(2-mercaptoethyl)] 1-[(2-carboxylato)pyrrolidin-1-yl]diazene-1-ium-1,2-diolate [S-acetyl-(2-mercaptoethyl)] ester into β -cyclodextrin.

β -Cyclodextrin (228 mg, 0.201 mmol) was mixed with 2 ml of water and heated to 65 °C to give a homogeneous solution. To the warm solution was added 76 mg (0.201 mmol) of O²-[S-acetyl-(2-mercaptoethyl)] 1-[(2-carboxylato)pyrrolidin-1-yl]diazene-1-ium-1,2-diolate [S-acetyl-(2-mercaptoethyl)] ester. Upon mixing, a white precipitate formed. The mixture was allowed to cool to room temperature and the product was collected by filtration, washed with water, and dried under vacuum to give 170 mg of product. An aqueous solution containing 33 mg of the O²-[S-acetyl-(2-mercaptoethyl)] 1-[(2-carboxylato)pyrrolidin-1-yl]diazene-1-ium-1,2-diolate [S-acetyl-(2-mercaptoethyl)] ester: β -cyclodextrin mixture exhibited an absorbance maximum at 232 nm and a molar absorptivity (ϵ) of 10.8 mM⁻¹cm⁻¹. Rates of NO release were measured as a function of time after immersing a 13

mg aliquot of the encapsulated material in 4 ml of phosphate buffer, pH 7.4, at 37 °C, with a chemiluminescence detector. A set of experiments was carried out in plain buffer, while another set was done in the presence of porcine liver esterase. A very small amount of NO was released in the absence of enzyme over a 400 hr period while a significant rate of NO production was observed when the enzyme was present in the buffer.

10

EXAMPLE 28

This example describes a general procedure for the preparation of O²-glycosylated diazeniumdiolates.

2,3,4,6-Tetraacetyl- α -D-glucopyranosyl bromide (acetobromoglucose) was prepared as described in Redemann et al., Org. Syn. Coll. Vol. III: 11-14 (1955).

2,3,4,6-Tetraacetyl- α -D-mannopyranosyl bromide (acetobromomannose) was prepared as described in Levene et al., J. Biol. Chem. 90: 247-250 (1931). Then, a slurry of 1 eq of a diazeniumdiolate in dimethylsulfoxide (DMSO) (0.5 mmol solid/ 1 ml of DMSO) was stirred with 0.03 eq of silver oxide at room temperature under nitrogen. A 0.5 M solution of 1.2 eq of acetobromomannose or acetobromoglucose in DMSO was injected dropwise and the mixture was stirred for three days. The resulting homogeneous solution was poured into 100 ml of ice-water and extracted with ether. The ether layer was washed with water, dried over sodium sulfate and treated with charcoal. The solution was filtered through magnesium sulfate, concentrated on a rotary evaporator, and dried under vacuum. The glucose derivatives were purified by recrystallization, while the glassy mannose adducts required column chromatography.

35 EXAMPLE 29

This example describes the preparation of sodium 1-(N,N-diethylamino)diazen-1-ium-1,2-diolate ("DEA/NO").

A solution of 119 g (1.63 mol) of diethylamine in 100 ml of 1:1 ether:acetonitrile was placed in a 500 ml Parr bottle. The solution was degassed, charged with 40 psi of nitric oxide, and allowed to stand at room temperature overnight. The pressure was released and the crystalline product was collected by filtration and dried under nitrogen to give 13 g of diethylammonium 1-(N,N-diethylamino)diazene-1-ium-1,2-diolate. The salt was treated with 10 ml of 10 M sodium hydroxide solution and the resulting paste was treated with 200 ml of ether to give the sodium salt. The sodium salt ("DEA/NO") was collected by vacuum filtration, washed with ether, and dried under vacuum to give 7.1 g of product: UV (in 0.01 N NaOH) λ_{\max} (ϵ) 250 ($6.88 \text{ mM}^{-1}\text{cm}^{-1}$); NMR (D_2O) δ 0.96 (t, 3 H), 2.94 (q, 2 H); in DMSO- d_6 δ 0.84 (t, 3 H) and 2.75 (q, 2 H).

EXAMPLE 30

This example describes the preparation of O^2 -(2,3,4,6-tetra-O-acetyl- α -D-glucopyranosyl) 1-(N,N-diethylamino)diazene-1-ium-1,2-diolate.

DEA/NO (2.98 g; 0.019 mol) in DMSO was reacted with acetobromoglucose (6.9 g; 0.017 mol) as described in the general procedure of Example 28. The product was recrystallized from petroleum ether to give 5.7 g (72%) 108 mg of a crystalline solid: mp 107-108°C; UV λ_{\max} (ϵ) 228 nm ($6.92 \text{ mM}^{-1}\text{cm}^{-1}$); NMR δ 1.11 (t, 6 H, $J = 7.11$), 2.02 (s, 3 H), 2.03 (s, 3 H), 2.04 (s, 3 H), 2.07 (s, 3 H), 3.21 (q, 4 H, $J = 7.12$), 3.81 (m, 1 H), 4.20 (m, 2 H), 5.14 (m, 1 H), 5.33 (m, 3 H). Anal. Calcd for $\text{C}_{18}\text{H}_{29}\text{N}_3\text{O}_{11}$: C, 46.65; H, 6.31; N, 9.07. Found: C, 46.73; H, 6.26; N, 9.01.

EXAMPLE 31

This example describes the deacylation of O^2 -(2,3,4,6-tetra-O-acetyl- α -D-glucopyranosyl) 1-(N,N-diethylamino)diazene-1-ium-1,2-diolate (from Example 30).

A solution of 253 mg (0.55 mmol) of the above compound in 5 ml of methanol was stirred with 10 μ l of 25% methanolic sodium methoxide. The progress of the reaction was monitored by TLC using 5:1 CH_2Cl_2 :ethyl acetate. The reaction was complete within 1 h at 25 °C.

Dowex-50W- H^+ resin (1 g) was added to the stirring methanolic solution. The mixture was filtered to remove the resin, and the methanolic solution was evaporated under vacuum to give 122 mg (75%) of O^2 -glucopyranosyl 1-(N,N-diethylamino)diazen-1-ium-1,2-diolate: UV λ_{max} (ϵ) 228 nm ($6.4 \text{ mM}^{-1} \text{ cm}^{-1}$); NMR (CDCl_3) δ 1.08 (t, 6H), 3.23 (9, 4H), 5.59 (m, 4H), 3.88 (m, 2H), 5.29 (m, 1H).

Surprisingly, the deacetylated product cleaved to the 1-(N,N-diethylamino)diazen-1-ium-1,2-diolate (DEA/NO) anion, then to NO, only extremely slowly at pH 3, despite its acetal-like structure. Even more surprisingly, the cleavage proceeded extremely rapidly at pH 13.

EXAMPLE 32

This example describes the preparation of sodium 1-[(1-ethoxycarbonyl)piperazin-4-yl]diazen-1-ium-1,2-diolate.

A solution of 20 g (0.126 mol) of carboethoxy piperazine in 60 ml of methanol was placed in a Parr bottle. The solution was treated with 27.4 ml (0.126 mol) of 25% sodium methoxide in methanol. The system was evacuated, charged with 40 psi of nitric oxide and kept at 25 °C for 48 hr. The white crystalline product was collected by filtration and washed with cold methanol as well as with copious amounts of ether. The product was dried under vacuum to give 14.5 g (48% yield) of sodium 1-[(1-ethoxycarbonyl)piperazin-4-yl]diazen-1-ium-1,2-diolate: mp: 184-185 °C; UV (0.01 N NaOH) λ_{max} (ϵ) 252nm ($10 \text{ mM}^{-1} \text{ cm}^{-1}$); NMR (D_2O) δ 1.25 (t, 3 H), 3.11 (m, 2 H), 3.68 (m, 2 H), 2.15 (q, 2 H). Anal calcd. for $\text{C}_6\text{H}_{13}\text{N}_4\text{O}_4\text{Na}$: C 35.00%, H 5.42%, N 23.33%, Na 9.58%. Found: C 34.87%, H 5.53%, N 23.26%, Na 9.69%. The half-life of this

compound at pH 7 and 25°C was estimated as 5 min. This measurement was based on the loss of the 252 nm chromophore in the ultraviolet spectrum.

5 EXAMPLE 33

This example describes the preparation of O²-(glucopyranos-2-yl) 1-[(1-ethoxycarbonyl)piperazin-4-yl]diazene-1-ium-1,2-diolate tetraacetate ester.

Acetobromoglucose (2.055 g; 0.005 mol) and 1.11 g
10 (0.00466 mol) of sodium 1-[(1-ethoxycarbonyl)piperazin-4-yl]diazene-1-ium-1,2-diolate were reacted as described above to give 624 mg (25%) of O²-(glucopyranos-2-yl) 1-[(1-ethoxycarbonyl)piperazin-4-yl]diazene-1-ium-1,2-diolate tetraacetate ester: UV λ_{\max} (ϵ) 228 nm (7.20 mM⁻¹
15 cm⁻¹); NMR δ 1.26 (t, 3 H), 2.02 (s, 3H), 2.03 (s, 3H), 2.04 (s, 3 H), 2.09 (s, 3 H), 3.46 (m, 4H), 3.68 (m, 4 H), 3.82 (m, 1 H), 4.17 (q, 2 H), 4.25 (m, 3 H), 5.27 (m, 3 H).

20 EXAMPLE 34

This example describes the preparation of O²-(mannopyranos-2-yl) 1-[(1-ethoxycarbonyl)piperazin-4-yl]diazene-1-ium-1,2-diolate tetraacetate.

Acetobromomannose (10.2 g ; 0.025 mol) and 5.28 g
25 (0.022 mol) of sodium 1-[(1-ethoxycarbonyl)piperazin-4-yl]diazene-1-ium-1,2-diolate were reacted as described above to give 6.4 g (53 %) of a glass: UV λ_{\max} (ϵ) 238 nm (7.5 mM⁻¹ cm⁻¹); NMR δ 1.29 (t, 3 H), 2.01 (s, 3H), 2.05 (s, 3H), 2.11 (s, 3 H), 2.17 (s, 3 H), 3.13 (m, 1 H),
30 3.50 (m, 4 H), 3.78 (m, 5 H), 4.19 (q, 2 H), 4.27 (m, 3 H), 5.28 (m, 3 H), 5.42 (m, 1H).

EXAMPLE 35

This example describes the preparation of an O²-glycosylated diazeniumdiolate directed to a mannose-fucose receptor.

- 5 Bis-[2-(N-ethoxycarbonylamino)ethyl]amine: A three-neck flask equipped with two dropping funnels was immersed in an ice-water bath. Diethylenetriamine (10.7 g, 0.104 mol) was placed in the cold flask and dissolved in 100 ml of 95% ethanol. To the cold solution was added 10 ml
10 (0.205 mol) of ethylchloroformate, dropwise. A solution of 10.6 g (0.1 mol) of sodium carbonate in 100 ml of distilled water was added simultaneously with 10 ml (0.205 mol) of ethylchloroformate. The reaction mixture was allowed to stir at room temperature overnight. The
15 ethanol was removed on a rotary evaporator and the aqueous portion was extracted with dichloromethane. The organic layer was washed with water, then extracted with 5% hydrochloric acid. The organic layer containing the neutral products was separated and set aside. The
20 aqueous layer was washed with dichloromethane and made basic with sodium hydroxide. The product was extracted into dichloromethane, dried over sodium sulfate, filtered through magnesium sulfate and evaporated to give 4 g of a colorless oil: NMR (CDCl₃) δ 1.25 (t, 6H), 2.78 (m, 4H),
25 3.36 (m, 4H), 4.14 (q, 4H), 5.13 (b, 2H).

- Sodium 1-[bis-(2-(N-ethoxycarbonylamino)ethyl)amino] diazen-1-ium-1,2-diolate: A solution of 2.6 g (0.011 mol) of bis-[2-(N-ethoxycarbonylamino)ethyl]amine in 20
30 ml of ether and 5 ml of methanol was placed in a 50 ml Parr bottle, treated with 2.4 ml (0.011 mol) of 25% methanolic sodium methoxide, degassed, cooled to -80 °C and charged with 50 psi of nitric oxide. A thick precipitate was observed after 3 hr of stirring. The
35 mixture was exposed to NO for 24 hr, the pressure was released, and the product was collected by filtration. The solid was washed with ether and dried under vacuum to





give 1.26 g (35%) of the diazeniumdiolate: mp 170-2 °C; UV λ_{\max} (ϵ) 252 nm ($7.6 \text{ mM}^{-1} \text{ cm}^{-1}$); NMR δ 1.24 (t, 6H), 3.19 (m, 8H), 4.11 (q, 4H).

- 5 O²-(Mannos-2-yl) 1-[bis-(2-(N-ethoxycarbonylamino)ethyl) amino]diazen-1-ium-1,2-diolate tetraacetate: A partial solution of 251 mg (0.763 mmol) of sodium 1-[bis-(2-(N-ethoxycarbonylamino)ethyl) amino]diazen-1-ium-1,2-diolate in 2 ml of dimethylsulfoxide (DMSO) was cooled to 0 °C
- 10 under nitrogen. To this was added 10 mg (0.06 mmol) of silver acetate, followed by the slow addition of 1 ml of a 0.82 M solution of acetobromomannose in tetrahydrofuran. The reaction mixture was allowed to stir at room temperature for 48 hr, poured over ice-
- 15 water, and extracted with ether. The ether solution was dried over sodium sulfate, filtered through a layer of magnesium sulfate, and evaporated under vacuum to give 307 mg of an oil: UV λ_{\max} 240 nm.
- 20 O²-(Mannos-2-yl) 1-[bis(2-aminoethyl) amino]diazen-1-ium-1,2-diolate]: A solution of 145 mg (0.23 mmol) of O²-(mannos-2-yl) 1-[bis-(2-(N-ethoxycarbonylamino)ethyl) amino]diazen-1-ium-1,2-diolate tetraacetate in a mixture of 0.2 ml of 10 N
- 25 NaOH, 2 ml of ethanol and 2 ml of water was heated at reflux for 15 hr. The solution was concentrated under vacuum and the remaining aqueous solution was extracted with dichloromethane. The aqueous solution was evaporated to dryness under vacuum. The residue was
- 30 taken up in methanol, put through a 10 g, 60 cc prepacked C-18 column, and eluted with methanol. The fractions exhibiting an absorption maximum at 236 nm were combined and evaporated to give 32 mg of a white powder: NMR (CD₃OD) δ 2.74 (t, 4H), 3.02 (t, 4H), 3.74 (m, 4H), 4.2
- 35 (m, 3H); UV λ_{\max} 238 nm.

EXAMPLE 36

This example describes the preparation of a combinatorial library using disodium 1-(2-carboxylato)pyrrolidin-1-yl diazen-1-ium-1,2-diolate
5 (PROLI/NO) as starting material.

The piperazine trityl resin 1, available from Calbiochem-Novabiochem Int'l. (San Diego, CA), is treated with sulfuryl chloride to form the chlorosulfonamide 2. Reaction of this resin with PROLI/NO gives compound 3.
10 The free carboxylic acid can be activated to 4 by reaction with dicyclohexyl carbodiimide (DCC) and N-hydroxysuccinimide. Nucleophilic addition of $R^{30}XH$ ($X=O, N, S$) to the resin-bound diazeniumdiolate provides a potentially large library of compounds, 5, substituted at
15 the carboxylato portion of the molecule. Base hydrolysis of 5 frees the anionic diazeniumdiolate 6 from the resin. This library, 6, may now be reacted with electrophiles $R^{31}X$ to form new sets of compound having structure 7.



All publications, patents and patent applications, cited herein are hereby incorporated by reference to the same extent as if each publication were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.

While this invention has been described with emphasis upon preferred embodiments, it will be obvious to those of ordinary skill in the art that the preferred

embodiments may be varied. It is intended that the invention may be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications encompassed within the spirit and scope
5 of the appended claims.

1. An O²-aryl substituted diazeniumdiolate having the formula

$$\begin{array}{c} \text{X}-\text{N} \rightarrow \text{O} \\ || \\ \text{N}-\text{O}-\text{O} \end{array}$$

(I)

10 wherein X is an organic moiety and Q is an aryl group,
wherein an atom of the ring of said aryl group is bonded
to the O²-oxygen.

2. The compound of claim 1, wherein Q is selected from the group consisting of an acridine, an anthracene, a benzene, a benzofuran, a benzothiophene, a benzoxazole, a benzopyrazole, a benzothiazole, a carbazole, a chlorophyll, a cinnoline, a furan, an imidazole, an indole, an isobenzofuran, an isoindole, an isoxazole, an isothiazole, an isoquinoline, a naphthalene, an oxazole, a phenanthrene, a phenanthridine, a phenothiazine, a phenoxazine, a phthalimide, a phthalazine, a phthalocyanine, a porphin, a pteridine, a purine, a pyrazine, a pyrazole, a pyridazine, a pyridine, a pyrimidine, a pyrrocoline, a pyrrole, a quinolizinium ion, a quinoline, a quinoxaline, a quinazoline, a sydnone, a tetrazole, a thiazole, a thiophene, a thyroxine, a triazine, and a triazole.

30 3. The compound of claim 1, wherein said atom of
said aryl ring bonded to said O²-oxygen is carbon or
nitrogen.

4. The compound of claim 1, wherein the Q moiety
35 is that of a vitamin or a derivative thereof.

5. The compound of claim 1, wherein the Q moiety is that of a hormone or a derivative thereof.

6. The compound of claim 2, wherein Q is dinitrophenyl or a derivative thereof.

7. The compound of claim 2, wherein Q is a pyrimidine or a derivative thereof.

8. The compound of claim 7, wherein Q is a ribosylpyrimidine or a derivative thereof.

9. The compound of claim 2, wherein Q is a purine or a derivative thereof.


10. The compound of claim 9, wherein Q is a ribosylpurine or a derivative thereof.

11. The O²-aryl diazeniumdiolate of claim 1, wherein X is linked to the N¹ nitrogen through an atom other than a carbon atom.

12. The O²-aryl diazeniumdiolate of claim 1, wherein X is a substituted or unsubstituted organic moiety selected from the group consisting of C₁-C₁₂ aliphatic, C₃-C₁₃ cycloalkyl, aryl, polycyclic, and aromatic polycyclic.

13. The O²-aryl diazeniumdiolate of claim 12, wherein said atom of said aryl ring bonded to said O²-oxygen is carbon or nitrogen.

14. The O²-aryl diazeniumdiolate of claim 1 having the formula




(II)

wherein b and d can be the same or different and may be zero or one, R¹, R², R³, R⁴, and R⁵ are the same or



different and are selected from the group consisting of hydrogen, C₃-C₈ cycloalkyl, C₁-₁₂ straight or branched chain alkyl, benzyl, benzoyl, phthaloyl, acetyl, trifluoroacetyl, p-toluyyl, t-butoxycarbonyl, or 2,2,2-tri-
 5 halo-t-butoxycarbonyl, and i, j, and k are the same or different and are integers from 2 to 12.

15. The O²-aryl diazeniumdiolates of claim 14, wherein said atom of said aryl ring bonded to said O²-
 10 oxygen is carbon or nitrogen.

16. An O²-aryl diazeniumdiolate of claim 1, having the formula




15 wherein D is



20 and wherein R¹⁰ and R¹¹ are the same or different and are selected from the group consisting of hydrogen, C₃-₈ cycloalkyl, C₁-₁₂ straight or branched chain alkyl, benzyl, benzoyl, phthaloyl, acetyl, trifluoroacetyl, p-toluyyl, t-butoxycarbonyl, and 2,2,2-trichloro-t-butoxycarbonyl, and
 25 f is an integer from 0 to 12.

17. The O²-aryl diazeniumdiolate of claim 16, wherein said atom of said aryl ring bonded to said O²-
 30 oxygen is carbon or nitrogen.

18. The O²-aryl diazeniumdiolate claim 1, having the formula:




35

(V)

wherein R^6 and R^7 can be the same or different and are chosen from H, C_1 - C_{12} straight chain alkyl, C_1 - C_{12} alkoxy or acyloxy substituted straight chain alkyl, C_2 - C_{12} hydroxy or halo substituted straight chain alkyl, C_3 - C_{12} branched chain alkyl, C_3 - C_{12} hydroxy, halo, alkoxy, or acyloxy substituted branched chain alkyl, C_3 - C_{12} straight chain olefinic and C_3 - C_{12} branched chain olefinic which are unsubstituted or which are substituted with hydroxy, alkoxy, acyloxy, halo or benzyl, provided that both R^6 and R^7 are not H; or R^6 and R^7 together with the nitrogen atom to which they are bonded form a heterocyclic ring.

19. The O^2 -aryl diazeniumdiolates of claim 18, wherein said atom of said aryl ring bonded to said O^2 -oxygen is carbon or nitrogen.

20. The O^2 -aryl diazeniumdiolate of claim 18, wherein R^6 and R^7 together with the nitrogen atom to which they are bonded form a heterocyclic ring selected from the group consisting of:




wherein A is N, O, or S, w is 1 to 12, y is 1 or 2, n is 1 to 5, R^8 is hydrogen, C_1 - C_8 straight chain alkyl, C_3 - C_8 branched chain alkyl, C_3 - C_8 cycloalkyl, unsubstituted or substituted aryl, such as phenyl, tolyl or the like, and R^9 is hydrogen, C_1 - C_6 straight chain alkyl or C_3 - C_6 branched chain alkyl.

21. The O^2 -aryl diazeniumdiolate of claim 20, wherein said atom of said aryl ring bonded to said O^2 -oxygen is carbon or nitrogen.


22. The O²-aryl diazeniumdiolate of claim 18,
wherein R⁶ is hydrogen.

23. The O²-aryl diazeniumdiolate of claim 22,
5 wherein said atom of said aryl ring bonded to said O²-
oxygen is carbon or nitrogen.


24. The O²-aryl diazeniumdiolate of claim 18,
wherein R⁶ and R⁷ are ethyl and Q is selected from the
10 group consisting of:



15



20



25

25. The O²-aryl diazeniumdiolate of claim 1, wherein
X is bound to a polymer.

30


26. The O²-aryl diazeniumdiolate of claim 25, wherein said atom of said aryl ring bonded to said O²-oxygen is carbon or nitrogen.

5 27. The O²-aryl diazeniumdiolate of claim 25, wherein said polymer is selected from the group consisting of a polyolefin, ~~or~~ polyurethane, a peptide, a protein, a polyethyleneimine, a starburst dendrimer, a polyamide, a polyether, a polyester, a nucleic acid, and a
10 polysaccharide.

28. The O²-aryl diazeniumdiolate of claim 27, wherein said polyolefin is selected from the group consisting of a polystyrene, a polyethylene, a
15 polytetrafluoroethylene, a polyvinylchloride, and a polyvinylidene difluoride.

29. The O²-aryl diazeniumdiolate of claim 27, wherein said polyamide is nylon.
20

30. An O²-aryl substituted diazeniumdiolate having the formula



25 wherein X is an inorganic moiety and Q is an aryl group, wherein an atom of the ring of said aryl group is bonded to the O²-oxygen.

31. The compound of claim 30, wherein X is ⁻O- or
30 ⁻O₃S-.

32. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
35

33. The pharmaceutical composition of claim 32, wherein said atom of said aryl ring bonded to said O²-oxygen is carbon or nitrogen.

5 34. A method of treating or preventing a biological disorder in an animal, wherein said disorder is treatable or preventable with nitric oxide, which method comprises administering to said animal an amount of a
10 compound of any of claims 1-31 sufficient to treat or prevent the biological disorder in said animal.

35. The method of claim 34, wherein said biological disorder is due to a genetic defect.

15 36. The method of claim 34, wherein said biological disorder is due to infection with an infectious agent.

37. The method of claim 36, wherein said infectious agent is a virus.

20

38. The method of claim 37, wherein said virus is a retrovirus.

25 39. The method of claim 38, wherein said animal is a human and said retrovirus is HIV.

40. The method of claim 39, wherein said HIV is HIV-1.

30 41. The method of claim 36, wherein said infectious agent is a bacterium.

42. The method of claim 41, wherein said bacterium is a Gram-positive bacterium.

35

43. The method of claim 36, wherein said infectious agent is a parasite.

44. The method of claim 43, wherein said parasite is *Giardia*.

5 45. A method of treating an animal infected with an infectious agent comprising a zinc finger protein that can be inactivated by a compound of any of claims 1-31, which method comprises administering to said animal an amount of a compound of any of claims 1-31 sufficient to
10 inactivate the zinc finger protein in said infectious agent so as to treat the infection in said animal.

46. The method of claim 45, wherein said zinc finger protein comprises a C-X2-C-X4-H-X4-C domain.
15

47. The method of claim 45, wherein said infectious agent is a virus.

48. The method of claim 47, wherein said virus is a retrovirus.
20

49. The method of claim 48, wherein said animal is a human and said retrovirus is HIV.

25 50. The method of claim 49, wherein said HIV is HIV-1.

51. The method of claim 46, wherein said infectious agent is a retrovirus.
30

52. The method of claim 45, wherein said infectious agent is a bacterium.

53. The method of claim 52, wherein said bacterium
35 is a Gram-positive bacterium.

54. The method of claim 45, wherein said infectious agent is a parasite.

55. The method of claim 54, wherein said parasite
5 is *Giardia*.

56. A method of treating an animal for cancer,
wherein said cancer involves a zinc finger protein that
can be inactivated by a compound of any of claims 1-31,
10 which method comprises administering to said animal an
amount of a compound of any of claims 1-31 sufficient to
inactivate the zinc finger protein so as to treat the
cancer in said animal.

15 57. A method of treating an animal for cancer,
wherein said cancer is resistant to treatment with a
chemotherapeutic agent, which method comprises
administering to said animal an amount of a compound of
any of claims 1-31 sufficient to render the cancer in the
20 animal treatable with the chemotherapeutic agent.

58. The method of claim 57, wherein said
chemotherapeutic agent is a DNA-damaging agent.

25 59. The method of claim 58, wherein said DNA
damaging agent is selected from the group consisting of
an alkylating agent and an oxidizing agent.

60. The method of claim 59, wherein said alkylating
30 agent is selected from the group consisting of
chlorambucil, melphalan and hepsulfam.

61. A method of treating a plant, plant cell or
tissue culture thereof, which is infected with an
35 infectious agent comprising a zinc finger protein that
can be inactivated by a compound of any of claims 1-31,
which method comprises contacting said plant, plant cell

or tissue culture thereof with an amount of a compound of any of claims 1-31 sufficient to inactivate the zinc finger protein in said infectious agent so as to treat the infection in said plant, plant cell or tissue culture
5 thereof.

62. The method of claim 61, wherein said infectious agent is a virus.


10 63. The method of claim 62, wherein said virus is selected from the group consisting of tobacco streak virus (TSV) and alfalfa mosaic virus (AIMV).

15 64. A method of modulating steroid hormone activity in a mammal, which is in need of modulation of steroid hormone activity and which comprises a steroid hormone receptor protein, which comprises a zinc finger and which can be inactivated by a compound of any of claims 1-31, which method comprises administering to said mammal an
20 amount of a compound of any of claims 1-31 sufficient to inactivate the steroid hormone receptor protein so as to modulate steroid hormone activity in said mammal.

25 65. A method of reducing on an inanimate object the presence of an infectious agent comprising a zinc finger protein that can be inactivated by a compound of any of claims 1-31, which method comprises contacting said inanimate object with an amount of a compound of any of claims 1-31 sufficient to inactivate the zinc finger
30 protein so as to reduce the presence of the infectious agent on said inanimate object.

35 66. The method of claim 65, wherein said infectious agent is selected from the group consisting of a virus, a bacterium, and a parasite.

67. An O²-glycosylated 1-substituted diazen-1-ium-1,2-diolate of Formula I:



10 in which R is a saccharide, which is attached to the O² of the diazeniumdiolate by the 2 position of a pyranose or furanose ring.

68. The compound of claim 67, wherein said saccharide is selected from the group consisting of a monosaccharide, a disaccharide, an oligosaccharide, and a polysaccharide.

69. The compound of claim 68, wherein said disaccharide is sucrose or maltose.


20 70. The compound of claim 68, wherein the monosaccharide is mannose, fucose or glucose.

71. The compound of claim 68, wherein said saccharide is a recognition sequence for receptor-mediated cellular phenomena.

72. The compound of claim 67, wherein said moiety X contains atoms other than carbon and hydrogen, and is linked to the nitrogen of the diazeniumdiolate through an atom other than carbon.


73. The compound of claim 67, wherein said moiety X is an amine, and is linked to the nitrogen of the diazeniumdiolate through a nitrogen atom.

35 74. An O²-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolate of formula II:



wherein R is any covalently bound organic or inorganic group other than hydrogen and R^{22} is hydrogen, hydroxyl, OM, wherein M is a cation, halo, $X^1R^{23}R^{24}$, wherein X^1 is O, N or S, and R^{23} and R^{24} are independently a C_{1-24} alkyl, a C_{3-24} cycloalkyl, a C_{2-24} olefinic, an aryl, or a heterocyclic group, and when X^1 is O or S, there is no R^{24} .

75. The compound of claim 74, wherein, X^1 is nitrogen and R^{23} and R^{24} , together with the nitrogen to which they are bonded, form a heterocyclic ring selected from the group consisting of:



in which A is O, N or S, w is 1-12, y is 1 or 2, z is 1-5, R^8 , R^9 , R^{25} , and R^{26} are hydrogen, a C_{1-8} straight chain alkyl, a C_{3-8} branched chain alkyl, a C_{3-8} cycloalkyl, or an aryl.

76. The compound of claim 74, wherein said moiety R is a C₁₋₁₂ straight chain alkyl, a C₃₋₁₂ branched chain alkyl, a C₂₋₁₂ straight chain or a C₃₋₁₂ branched chain olefinic, a C₁₋₁₂ acyl, sulfonyl, carboxamido, a glycosyl group, an aryl group or a group of the formula $-(CH_2)_n-ON=N(O)NR^{28}R^{29}$, wherein n is an integer of 2-8, and R²⁸ and R²⁹ are independently a C₁₋₁₂ straight chain alkyl, a C₃₋₁₂ branched chain alkyl, or a C₂₋₁₂ straight chain or a C₃₋₁₂ branched chain olefinic, or R²⁸ and R²⁹, together with the nitrogen atom to which they are bonded, form a heterocyclic group selected from the group consisting of a pyrrolidino, a piperidino, a piperazino and a morpholino group.

15

77. The compound of claim 76, wherein said moiety R is substituted.

78. A composition comprising a compound of any of claims 67-77.

79. A method of treating or preventing a biological disorder in an animal, wherein said disorder is treatable or preventable with nitric oxide, which method comprises administering to the animal an amount of a compound of any of claims 67-77 sufficient to treat or prevent the biological disorder.

80. The method of claim 79, wherein said biological disorder is selected from the group consisting of infection, inflammation, metastasis, fulminant liver failure, malaria, a respiratory disorder, impotence, a cardiovascular disorder and a hematologic disorder.

81. The method of claim 80, wherein said infection is due to an agent selected from the group consisting of a virus, a bacterium and a parasite.

82. The method of claim 81, wherein said parasite is *Leishmania*.

5 83. The method of claim 82, wherein said compound is a compound of any claims 67-73.

10 84. A method of inactivating or inhibiting a zinc finger protein, which method comprises contacting said zinc finger protein with an amount of a compound of any of claims 1-31 sufficient to inactivate or inhibit said zinc finger protein.




FIG. 1




FIG. 2

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/17267

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D295/22

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 93 07114 A (THE UNITED STATES OF AMERICA, SECRETARY DEPARTMENT OF HEALTH AND HUMAN) 15 April 1993 see the whole document ---	1-33
A	US 5 039 705 A (UNITED STATES OF AMERICA, DEPARTMENT OF HEALTH AND HUMAN RESOURCES) 13 August 1991 cited in the application see the whole document ---	1-33
P, A	WO 96 40665 A (THE UNITED STATES OF AMERICA, SECRETARY, DEPARTMENT OF HEALTH AND HUMAN) 19 December 1996 see the whole document ---	1-33

-/-

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z" document member of the same patent family

Date of the actual completion of the international search

15 January 1998

Date of mailing of the international search report

20. 01. 98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Luyten, H

INTERNATIONAL SEARCH REPORT

Inta. Application No
PCT/93/97/17267

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 366 997 A (THE UNITED STATE S OF AMERICA, SECRETARY DEPARTRMENT OF HEALTH AND HUMA) 22 November 1994 cited in the application see the whole document ---	1-33
A	US 5 208 233 A (THE UNITED STATES OF AMERICA, SECRETARY , DEPARTMENT OF HEALTH AND HUMAN) 4 May 1993 cited in the application see the whole document -----	1-33

INTERNATIONAL SEARCH REPORT

national application No.

PCT/US 97/ 17267

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 34-84
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/17267

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9307114 A	15-04-93	AU 668107 B	26-04-96
		AU 2669092 A	03-05-93
		CA 2119572 A	15-04-93
		DE 69223157 D	18-12-97
		EP 0605622 A	13-07-94
		JP 7502265 T	09-03-95
		US 5366997 A	22-11-94
US 5039705 A	13-08-91	AT 130191 T	15-12-95
		AU 638499 B	01-07-93
		AU 6522690 A	18-04-91
		CA 2066409 A,C	16-03-91
		DE 69023660 D	21-12-95
		DE 69023660 T	05-06-96
		EP 0491864 A	01-07-92
		ES 2082005 T	16-03-96
		JP 7098747 B	25-10-95
		JP 5501402 T	18-03-93
		WO 9104022 A	04-04-91
		US 5208233 A	04-05-93
WO 9640665 A	19-12-96	AU 6271496 A	30-12-96
US 5366997 A	22-11-94	AU 668107 B	26-04-96
		AU 2669092 A	03-05-93
		CA 2119572 A	15-04-93
		DE 69223157 D	18-12-97
		EP 0605622 A	13-07-94
		JP 7502265 T	09-03-95
		WO 9307114 A	15-04-93
US 5208233 A	04-05-93	US 5039705 A	13-08-91
		AT 130191 T	15-12-95
		AU 638499 B	01-07-93
		AU 6522690 A	18-04-91
		CA 2066409 A,C	16-03-91
		DE 69023660 D	21-12-95
		DE 69023660 T	05-06-96
		EP 0491864 A	01-07-92
		ES 2082005 T	16-03-96

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. onal Application No

PCT/US 97/17267

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5208233 A		JP 7098747 B	25-10-95
		JP 5501402 T	18-03-93
		WO 9104022 A	04-04-91



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 295/22	A1	(11) International Publication Number: WO 98/13358
		(43) International Publication Date: 2 April 1998 (02.04.98)

(21) International Application Number: PCT/US97/17267

(22) International Filing Date: 26 September 1997 (26.09.97)

(30) Priority Data:

60/026,816	27 September 1996 (27.09.96)	US
60/045,917	7 May 1997 (07.05.97)	US
60/051,696	3 July 1997 (03.07.97)	US

(71) Applicant (for all designated States except US): THE UNITED STATES OF AMERICA represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institute of Health [US/US]; Office of Technology Transfer, Suite 325, 6011 Executive Boulevard, Rockville, MD 20852 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SAAVEDRA, Joseph, E. [US/US]; 7189 Browns Lane, Thurmount, MD 21788 (US). KEEFER, Larry, K. [US/US]; 7016 River Road, Bethesda, MD 20817 (US). SRINIVASAN, Aloka [IN/US]; 7 Livingstone Terrace, Frederick, MD 21702 (US). BOGDAN, Christian [DE/DE]; Freidrich-Alexander-Universitat, Erlangen-Numberg, Institut Fur Klinische, Mikrobiologie und Immunologie, Wasserturmstrasse, D-91054 Erlangen (DE). RICE, William, G. [US/US]; 625 Magnolia Avenue, Fred-

erick, MD 21701 (US). JI, Xinhua [CN/US]; 10218 Crested Iris Drive, Gaithersburg, MD 20879 (US).

(74) Agents: GAGALA, Bruce, M. et al.; Leydig, Voit & Mayer, Ltd., Two Prudential Plaza, Suite 4900, 180 North Stetson, Chicago, IL 60601-6780 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: O²-ARYLATED OR O²-GLYCOSYLATED 1-SUBSTITUTED DIAZEN-1-IUM-1,2-DIOLATES AND O²-SUBSTITUTED 1-[(2-CARBOXYLATO)PYRROLIDIN-1-YL]DIAZEN-1-IUM-1,2-DIOLATES

(57) Abstract

Diazeniumdiolates, wherein the N¹ position is substituted by an inorganic or organic moiety and the O²-oxygen is bound to a substituted or unsubstituted aromatic group, are provided. Also provided are O²-glycosylated 1-substituted diazen-1-ium-1,2-diolates (O²-glycosylated diazeniumdiolates) and O²-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates (1-[(2-carboxylato)pyrrolidin-1-yl]diazeniumdiolates). The O²-aryl diazeniumdiolates are stable with respect to the hydrolytic generation of nitric oxide in neutral to acidic solutions and generate nitric oxide in basic or nucleophilic environments or microenvironments. Also provided are compositions, including pharmaceutical compositions, comprising such compounds and methods of using such compounds.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		